

**US DEPARTMENT OF LABOR  
OFFICE OF WORKERS' COMPENSATION PROGRAMS  
ESTIMATE OF EEOICPA LIABILITIES AS OF  
SEPTEMBER 30, 2011**



# MADISON CONSULTING GROUP

Actuaries • Property/Casualty Consulting Services

---

November 4, 2011

Ms. Cecily Rayburn  
Director, Division of Planning, Policy and Standards  
Office of Workers' Compensation Programs  
US Department of Labor  
Frances Perkins Building  
200 Constitution Ave., NW  
Washington, DC 20210

RE: Estimate of EEOICPA Liabilities  
As of September 30, 2011

Dear Ms. Rayburn:

Please find enclosed a copy of the above captioned report. We have enjoyed working on this project and hope you find the results satisfactory. Please let us know should you have any questions.

Sincerely,

A handwritten signature in cursive script that reads "John Gleba".

John Gleba, FCAS, MAAA

JG/ms  
Enclosure

**US DEPARTMENT OF LABOR  
OFFICE OF WORKERS' COMPENSATION PROGRAMS  
ESTIMATE OF EEOICPA LIABILITIES AS OF SEPTEMBER 30, 2011**

**PURPOSE**

Madison Consulting Group was requested by the Office of Workers' Compensation Programs ("OWCP"), a division of the United States Department of Labor ("DOL") to aid in estimating liabilities as of September 30, 2011 under the Energy Employees Occupational Illness Compensation Program Act ("EEOICPA"). This report, including the attached exhibits documents our review.

**DISTRIBUTION AND USE**

This report was prepared to aid OWCP in their review of EEOICPA liabilities as of September 30, 2011. We understand a copy of this report may be provided to OWCP's auditors. It is requested that all distributions of this report be in its entirety, including the attached exhibits.

**ACKNOWLEDGEMENT OF QUALIFICATION**

This report was prepared under the direction of John Gleba, FCAS, MAAA and was peer reviewed by Mark Crawshaw, Ph.D., FCAS, MAAA. Both Messrs. Gleba and Crawshaw are members of the American Academy of Actuaries and meet the Qualification Standards of the American Academy of Actuaries to render the actuarial opinion contained herein.

## EXECUTIVE SUMMARY

The Energy Employees Occupational Illness Compensation Program Act became effective July 31, 2001 and provides indemnity and medical benefits to claimants who are (or were) employed in various energy related activities either directly for the Department of Energy (“DOE”) or through its contractors or subcontractors. Eligible claimants also include survivors of deceased workers who otherwise would have been available for benefit payments.

Both Part B of the Act, effective July 31, 2001, and Part E of the Act, effective October 28, 2004, provide lump sum compensation to qualified workers and to certain survivors as well as ongoing medical benefits to qualified workers.

Part B provides compensation of \$150,000 and medical expenses to employees of the Department of Energy (or its contractors or subcontractors) who develop cancer after working at a covered facility. Part B also covers employees who are a member of the Special Exposure Cohort (“SEC”), which is defined as workers who were employed at least 250 days before February 1, 1992 at specific Gaseous Diffusion Plants or certain Underground Nuclear Testing sites. If the employee is no longer living, compensation benefits are available to survivors. Part B also covers exposure to beryllium, employees who develop chronic silicosis and uranium workers who were previously awarded benefits under Section 5 of the Radiation Exposure Compensation Act (“RECA”).

Part E provides variable compensation up to \$250,000 for employees of the DOE, its contractors or subcontractors, or their survivors, who develop an illness due to exposure to toxic substances at certain DOE worksites. Toxic substances include exposure to radiation, as

well as exposure to certain chemicals, solvents, acids, and metals. Compensation includes wage loss, impairment, and survivor benefits.

#### Summary of Outstanding Liabilities as of September 30, 2011

Exhibit 1, Sheet 1 shows the total estimated undiscounted liability as of September 30, 2011 of \$22,633 million on an undiscounted basis and \$15,146 million on a discounted basis. Exhibit 1 also provides the liabilities separate between Part B and Part E.

Liabilities have increased 14.3% on an undiscounted basis and 25.0% on a discounted basis in total compared to the comparable estimates as of September 30, 2010. By component, Part B liabilities have decreased 0.6% on an undiscounted basis and increased 14.6% on a discounted basis. Part E liabilities have increased by 42.6% on an undiscounted basis and 45.1% on a discounted basis. On a combined basis, the liabilities have increased due to:

- Increased number of cancer Special Exposure Cohort (“SEC”) claims;
- Increased number of projected approvals for Part E cases;
- Higher projected medical costs; and
- A lower discount rate.

For informational purposes, Exhibit 1, Sheet 2 splits out those payments made on behalf of the DOJ on RECA claims from the total liabilities.

## OVERVIEW OF THE EEOICPA ANALYSIS

The analysis is performed using data extracts provided by the DOL. Data provided included information on medical payments by claim and by case, compensation payments by claim and case, claim disposition status (e.g., approved, denied, pending decision, etc.), and employee data such as date of birth, sex, date of death, and survivor information.

The analysis provides separate estimates for compensation and medical and further splits the estimates between Part B and Part E. For medical cases, historical data is used to project ultimate case count and an average medical award. For compensation cases, historical data is used to estimate the number of cases that will be approved for benefits and the average award by case. For the purposes of this analysis, each case represents one employee. An individual case may have one or many claims assigned to it. The following section describes the source data in more detail.

### Source Data Provided by the DOL

The data provided for this analysis consisted of a series of data extracts, or “tables” that were imported into an Access database for further analysis and manipulation. The source data included the following tables:

<b>Table Name</b>	<b>Description</b>
All_csh	Claim status (e.g., approved, denied, etc.) by claim ID for Part B claims
All_ecsh	Claim status (e.g., approved, denied, etc.) by claim ID for Part E claims
Bclaim	Claim information included type of claim, filing date, and RECA indicator for Part B claims
Bp_hist	History of medical payments by case
Cas	Employee information by case (e.g., date of birth, sex, dependent information)
CLAIM STATUS	Description of claim status codes in All_csh and All_ecsh tables
E_pay_aop	Breakout of Part E awards by impairment, lump sum, and wage loss
Eclaim	Claim information included type of claim and filing date, and RECA indicator for Part E claims
EFDA_Dates	Approval dates for Part E claims
Emed_condition	Information on medical condition (e.g., disease type) for Part E claims
Emp_sec	Claims identified as belonging to the Special Exposure Cohort (“SEC”)
Emp_worksite	Employment dates at worksites by case
Epayment	History of Part E awards by claim
FDA_Dates	Approval dates for Part B claims

Table Name	Description
MED_COND_DESCRIP	Description of medical condition codes for Med_condition and Emed_condition tables
Med_condition	Information on medical condition (e.g., disease type) for Part B claims
Payment	History of Part B awards by claim
RECA_eft	Additional RECA payments (electronic funds transfer)
RECA_paper_check	Additional RECA payments (paper check)

Using the information from the above tables, a series of data compilations were performed to extract raw summary data. These tables are shown in Exhibit 3 and include the following:

Exhibit 3 – Table 1 – Number of Cases and Claims by Disease

Summary information on the number of cases (e.g., employees) and case split between Part B and Part E. Part B cases and claims are further segregated by disease.

The disease categories shown in Table 1 represent the “governing disease” for each claim or case. Because a single case can involve multiple medical conditions, a hierarchy was established to generate a governing disease category for each case. The hierarchy involved assigning a governing disease in the following priority order:

- a. RECA cases – identified from the Bclaim and Eclaim table when:
  - i. There is a positive dollar amount in the RECA\_AMT\_DOJ\_PD field or;
  - ii. A value of “4”, “5” or “Y”, in the RECVD\_RECA\_IND
- b. Beryllium Disease (“BD”) cases – identified with a value of “BD” in the COND\_TYPE field from the Med\_condition table.
- c. Chronic Silicosis (“CS”) cases – identified with a value of “CS” in the COND\_TYPE field from the Med\_condition table.
- d. Cancer SEC (“CN-SEC”) cases – any case identified as a Special Exposure Cohort:
  - i. The claim ID exists in the Emp\_sec table or;
  - ii. There is a value of “SE”, “SEF”, or “SER” in the CLAIM\_STATUS\_CD field in the All\_csh table.

- e. Cancer Non SEC (“CN-NONSEC”) cases - identified with a value of “CN” in the COND\_TYPE field from the Med\_condition table (and not previously identified as a CN-SEC case).
- f. Beryllium Sensitivity (“BS”) cases - identified with a value of “BS” in the COND\_TYPE field from the Med\_condition table.
- g. Other Lung (“OL”) cases - identified with a value of “OL” in the COND\_TYPE field from the Med\_condition table.
- h. Renal (“RN”) cases - identified with a value of “RN” in the COND\_TYPE field from the Med\_condition table.
- i. All other diseases, unknown cases – identified with any other value in the COND\_TYPE field not listed above (excluding “99”, see below) from the Med\_condition table. These include miscellaneous diseases such as diabetes, heart conditions, mercury poisoning, etc. plus any cases where the COND\_TYPE field is blank.
- j. Other, not listed (“99”) cases – identified with a value of “99” in the COND\_TYPE field from the Med\_Condition table.

#### Exhibit 3 – Table 2 – Cases filed by Disease

This table shows the number of cases filed by either an employee, an employee’s survivor, or both. The determination of who filed a case was based on the CLAIM\_TYPE field from the Bclaim and Eclaim tables. A CLAIM\_TYPE of “EM” indicated a claim filed by an employee, while any other CLAIM\_TYPE was assumed to represent a survivor.

#### Exhibit 3 – Table 3 – Average Age of Employee at Time Claim is Filed

This table shows the average age of employee at the time a claim is filed, split between Part B and Part E cases. The age at filing was generated from the filed dates in the Bclaim and Eclaim tables (CLAIM\_FILED\_DT field) and the employee information from the Cas table.



#### Exhibit 3 – Table 4 – Sex of Employee

This table shows the distribution of filed cases by sex of employee. This information was generated using employee information from the Cas table.

#### Exhibit 3 – Table 5 – Actual Cases Approved by Quarter

Table 5 shows the number of actual cases approved by quarter, split between Part B and Part E. Part B approvals are further split by governing disease. This information came from the FDA\_Dates and EFDA\_Dates tables.

#### Exhibit 3 – Table 6 – Compensation Actual Dollars Paid by Quarter

Table 6 shows actual historical compensation dollars paid (including wage loss, impairment, and lump sum awards) split between Part B and Part E. Part B payments are further split by governing disease. This information was generated from the Payment and Epayment tables.

#### Exhibit 3 – Table 7 – Number of Cases Paid Compensation by Quarter

Table 7 shows the number of historical paid cases corresponding to the dollar amounts in Table 6.

#### Exhibit 3 – Table 8 – Number of Paid Cases by Living Employee (Not Survivor)

Table 8 shows the number of paid cases involving a living employee split between Part B and Part E. Part B cases are further split by governing disease. This information came from the Payment and Epayment tables and involved counting cases where the

PAYEE\_TYPE field contained “EM” and the STATUS field contained either a “T”, a “K”, or a “P”.

#### Exhibit 3 – Table 9 – Medical Actual Dollars Paid by Quarter

Table 9 shows actual historical medical dollars paid (including wage loss, impairment, and lump sum awards) split between Part B and Part E. Part B payments are further split by governing disease. This information was generated from the Bphist table.

For the purposes of determining whether medical payments should be coded as Part B or Part E, the following algorithm was used:

- If a particular CASE\_ID value appeared in both the Bclaim and Eclaim tables, the entire case was coded as Part B.
- If a particular CASE\_ID value appeared only in the Bclaim table (but not the Eclaim table), the entire case was coded as Part B.
- If a particular CASE\_ID value appeared only in the Eclaim table (but not the Bclaim table), the entire case was coded as Part E.

Thus, the medical dollars shown for Part E in Column (13) of Table 9 are only those cases that had one (or more) Part E claims but no companion Part B claims.

#### Exhibit 3 – Table 10 –Number of Cases Medical by Quarter

Table 10 shows the number of historical paid cases corresponding to the dollar amounts in Table 9.

#### Exhibit 3 – Calculation of Average Part E Benefit (Sheet 11)

Exhibit 3, Sheets 11a and 11b provide the underlying data used to estimate an Average Part E benefit per case. Information from the E\_pay\_aop table is used to figure the

average benefit related to impairment, lump sum, and wage loss individually. Average payments to survivors (excluding employees) are also generated from the E\_pay\_aop table.

Based on this data, an average Part E benefit of \$123,000 is selected (see bottom of Sheet 11b). For comparison purposes, the average Part E benefit selected in the prior actuarial analysis was \$142,000.

## METHODOLOGY

As noted above, the general methodology involves projecting the estimating number of cases that will be paid in the future for either medical or compensation and the average payment per case. The following section describes this methodology in more detail.

### Exhibit 2 – Projection of Estimated Annual Medical Benefits by Case

Exhibit 2, Sheet 1 shows the calculation of the average annual medical benefits by case, split between Part B and Part E.

To start, actual historical data is used to calculate the average quarterly medical costs by case for Part B and Part E combined and separately. This is shown on Sheets 2 through 8 of Exhibit 2.

Sheet 4, for example, shows the calculation for Part B RECA cases. In Columns (2) and (3) of Exhibit 4, the number of cases eligible for medical benefits is generated from the raw data provided by the DOJ. Cases eligible for medical benefits are all cases where the employee is still living, whether or not actual medical benefits have been paid. Column 4 provides the actual medical payments from Exhibit 3, Table 9.

In Column (6), the actual medical dollars are adjusted to current level using historical CPI indices for medical care services. The resulting current level dollars are divided by the number of eligible case to determine the average quarterly medical payments in Column (7).

Similar calculations are made for the remaining disease categories and for Part E on Sheets 5 through 8.

On Sheet 1, a quarterly medical payment at current level is selected for both Part B cases and Part E cases. For Part B cases, the selected quarterly payment of \$4,000 implies an annual payment of \$16,000. For Part E cases, the selected quarterly payment of \$1,600 implies an annual payment of \$6,400. For comparison purposes, the annual medical payments assumed in the prior actuarial report were \$15,000 and \$4,800 for Parts B and E respectively.

The last step is to project future years annual medical payments based on the selected current level payment and as assumed trend rate. For the purposes of this analysis, we have selected an annual trend of 1.5%. We note that in the prior actuarial report, the selected annual trend was 6.0%.

The selected trend rate of 1.5% was selected after careful review of various trends embedded in the historical data compiled in Sheets 2 through 8. In particular, we note that while logic would generally dictate that medical costs increase at a level consistent with economic indicators, the trends in the actual data do not exhibit this pattern. In some cases, medical benefits increase from one year over another; in other instances medical benefits decrease. We believe that this is due to the nature of the EEOICPA program itself, in that imbedded trends do not always follow overall trends in other public sectors.

#### Exhibit 4 - Projection of Future Approved Cases (Compensation)

Exhibit 4 outlines the general approach to estimating future approval cases that will be subject to compensation awards. Sheets 1 through 6 provide estimates for Part B cases by disease while Sheet 7 projects approvals for Part E cases. The following will describe the methodology for Part B, RECA cases (Exhibit 4, Sheet 1).

Column (4) of Sheet 1 shows actual approved cases by quarter from October 2001 through June 2011. This information comes from Exhibit 3, Table 5 as described earlier. Based on the actual data, a forecast is made for all future quarters through September 2031. The methodology involved looking at average approval rates and fitting actual data to trend lines and extrapolating a “best fit” for future quarters.

Column (5) provides the actual case amount by award. Historical case amounts were provided by the DOJ. Future case amounts assume no change to the current benefit law and that current award levels will remain constant into the future.

Column (6) is the product of the number of approved cases in Column (4) (actual and projected) times the case amounts in Column (5). Column (7) provides a summary of approved cases by filed year. Filed years are assumed to run from July to June (e.g., 3Q through 2Q of the following year).

A similar process was done for other Part B disease categories and for Part E in Sheets 2 through 6.

Exhibit 5, Sheet 1 provides a summary of the projected approved cases by fiscal year from Exhibit 4 by category.

#### Exhibit 5, Sheet 2 - Estimated Number of Paid Cases by Fiscal Year

Exhibit 5, Sheet 2 shows the estimated number of paid cases by fiscal year. For fiscal years through September 30, 2011, the data represents actual cases paid from Exhibit 3, Table 7. For projected amounts, an assumption was made that every approved case will be paid in the same year as it is approved. In other words, there is no assumed lag between the time a case is approved and a case is paid. Although this is a different assumption than used in the prior

actuarial report, we based this assumption on information provided directly by employees of the DEEOIC.

#### Exhibit 5, Sheet 3 - Estimated Cases Eligible for Medical Expenses

Exhibit 5, Sheet 3 provides an estimate of the projected number of cases eligible for medical expenses. Actual data through September 2011 comes from Exhibit 3, Table 8.

For projected cases, it is noted that only approved cases where the employee is still living are eligible for medical expenses in the future. Therefore, the projected number of “new” medical cases by disease in Columns (2) through (7) and Column (9) are the product of the estimated number of approved cases from Exhibit 5, Sheet 1, times a percentage representing the number of cases filed by living employees from Exhibit 3, Table 2. Note that the underlying assumption is that every approved case will also involve medical benefits. While this may or may not be true in actuality, this represents a conservative assumption with regards to projected future liabilities.

Columns (10) and (11) represent “ongoing” medical cases projected through 2036. Ongoing medical cases are the cumulative sum of “new” medical cases for the current year plus all prior years, adjusted for mortality.

#### Exhibit 6 - Estimated Dollars Paid by Fiscal Year

Columns (2) through (8) show the estimated compensation dollars paid by Part B disease category. Actual data through September 2011 comes from Exhibit 3, Table 6. Projected data through 2031 is based on the number of projected paid cases from Exhibit 5, Sheet 2 times the average award amount by disease (\$50,000 (top off) for RECA Non-DOJ,

\$100,000 for RECA benefits paid by DOJ, \$0 for beryllium sensitive and \$150,000 for everything else.

Column (11) provides the estimated compensation dollars paid for Part B cases. As above, actual data through September 2011 comes from Exhibit 3, Table 6. Projected data through 2046 is based on the number of approved cases from Exhibit 5, Sheet 1 times the average Part E benefit of \$123,000 (see Exhibit 3, Sheet 11b).

Column (9) shows projected medical benefits for Part B cases through 2065. The information is the product of the “ongoing” medical cases from Exhibit 5, Sheet 3, Column (10) and the average Part B medical benefit shown on Exhibit 2, Sheet 1. Similarly, Column (12) shows projected medical benefits for Part E cases through 2065.

Column (14) shows the total projected payments for the entire program combined. This information is summarized on Exhibit 1, Sheet 1 for fiscal years 2011 and forward and represents the expected future liability for the EEOICPA program.

### Summary of Outstanding Liabilities

Exhibit 1, Sheet 1 summarizes the projected future liabilities for Part B and Part E separately. The undiscounted liabilities are from corresponding figures on Exhibit 6. Discounted liabilities assume a 4.025% discount rate based on current OMB projections.

On Exhibit 1, Sheets 2 and 3, RECA payments made on behalf of the DOJ are segregated out for informational purposes. Sheet 2 segregates the undiscounted liability; Sheet 3 segregates the discounted liability.



**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF OUTSTANDING LIABILITIES**

	Part B	Part E	Total
Undiscounted Future Liability	\$ 12,913,682,953	\$ 9,719,220,076	\$ 22,632,903,029
Discounted Liability (4.025% Interest Rate)	\$ 9,126,431,358	\$ 6,019,345,993	\$ 15,145,777,352

Fiscal Year	Years of Discount	Discount Factor	PART B Undiscounted Payout (a)	PART B Discounted Payout (b)	PART E Undiscounted Payout (a)	PART E Discounted Payout (c)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
10/11 - 9/12	0.50	0.98046	\$ 851,075,600	\$ 834,447,999	\$ 429,824,427	\$ 421,426,878
10/12 - 9/13	1.50	0.94253	833,925,842	785,996,922	426,278,933	401,779,046
10/13 - 9/14	2.50	0.90606	815,840,313	739,198,114	422,047,353	382,399,107
10/14 - 9/15	3.50	0.87100	796,398,250	693,662,571	417,129,590	363,319,713
10/15 - 9/16	4.50	0.83730	774,573,698	648,549,286	411,529,220	344,572,741
10/16 - 9/17	5.50	0.80490	750,782,226	604,305,432	405,254,044	326,189,421
10/17 - 9/18	6.50	0.77376	725,344,569	561,240,696	398,316,515	308,200,334
10/18 - 9/19	7.50	0.74382	697,352,074	518,703,482	390,733,995	290,635,235
10/19 - 9/20	8.50	0.71504	667,141,324	477,031,639	382,528,744	273,522,726
10/20 - 9/21	9.50	0.68737	634,610,168	436,213,040	373,727,643	256,889,788
10/21 - 9/22	10.50	0.66078	599,824,390	396,349,226	364,361,631	240,761,217
10/22 - 9/23	11.50	0.63521	563,023,589	357,637,261	354,464,897	225,159,047
10/23 - 9/24	12.50	0.61063	523,826,289	319,864,273	344,073,901	210,101,995
10/24 - 9/25	13.50	0.58700	482,292,192	283,107,223	333,226,308	195,605,022
10/25 - 9/26	14.50	0.56429	438,652,752	247,527,727	321,959,943	181,679,045
10/26 - 9/27	15.50	0.54246	392,845,855	213,101,961	310,311,834	168,330,808
10/27 - 9/28	16.50	0.52147	345,775,615	180,310,870	298,317,372	155,562,922
10/28 - 9/29	17.50	0.50129	296,776,716	148,771,468	286,008,989	143,373,704
10/29 - 9/30	18.50	0.48189	246,092,558	118,590,685	273,410,352	131,754,984
10/30 - 9/31	19.50	0.46325	195,900,005	90,750,457	260,537,182	120,693,556
After 9/31			1,281,628,929	471,071,028	2,515,177,202	877,388,705
<b>Total</b>			<b>\$ 12,913,682,953</b>	<b>\$ 9,126,431,358</b>	<b>\$ 9,719,220,076</b>	<b>\$ 6,019,345,993</b>

Notes: (a) See Exhibit 6.  
(b) [ (3) × (4) ]  
(c) [ (3) × (6) ]

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### SUMMARY OF OUTSTANDING LIABILITIES SEPARATING OUT PAYMENTS ON DOJ RECA SECTION 5 - UNDISCOUNTED

Fiscal Year	Part B Excluding Payments on Behalf of DOJ on RECA			Payments on Behalf of DOJ on RECA	
	Claims (a)	Part E (a)	(2) + (3)	Claims (a)	(4) + (5)
(1)	(2)	(3)	(4)	(5)	(6)
10/11 - 9/12	\$ 821,975,600	\$ 429,824,427	\$ 1,251,800,027	\$ 29,100,000	\$ 1,280,900,027
10/12 - 9/13	808,625,842	426,278,933	1,234,904,775	25,300,000	1,260,204,775
10/13 - 9/14	793,540,313	422,047,353	1,215,587,666	22,300,000	1,237,887,666
10/14 - 9/15	776,498,250	417,129,590	1,193,627,840	19,900,000	1,213,527,840
10/15 - 9/16	756,773,698	411,529,220	1,168,302,918	17,800,000	1,186,102,918
10/16 - 9/17	734,882,226	405,254,044	1,140,136,270	15,900,000	1,156,036,270
10/17 - 9/18	710,844,569	398,316,515	1,109,161,084	14,500,000	1,123,661,084
10/18 - 9/19	684,352,074	390,733,995	1,075,086,070	13,000,000	1,088,086,070
10/19 - 9/20	655,441,324	382,528,744	1,037,970,068	11,700,000	1,049,670,068
10/20 - 9/21	624,110,168	373,727,643	997,837,811	10,500,000	1,008,337,811
10/21 - 9/22	590,524,390	364,361,631	954,886,020	9,300,000	964,186,020
10/22 - 9/23	554,723,589	354,464,897	909,188,487	8,300,000	917,488,487
10/23 - 9/24	516,626,289	344,073,901	860,700,190	7,200,000	867,900,190
10/24 - 9/25	476,192,192	333,226,308	809,418,499	6,100,000	815,518,499
10/25 - 9/26	433,552,752	321,959,943	755,512,695	5,100,000	760,612,695
10/26 - 9/27	388,745,855	310,311,834	699,057,689	4,100,000	703,157,689
10/27 - 9/28	342,675,615	298,317,372	640,992,987	3,100,000	644,092,987
10/28 - 9/29	294,676,716	286,008,989	580,685,705	2,100,000	582,785,705
10/29 - 9/30	244,992,558	273,410,352	518,402,910	1,100,000	519,502,910
10/30 - 9/31	195,700,005	260,537,182	456,237,186	200,000	456,437,186
After 9/31	1,281,628,929	2,515,177,202	3,796,806,131	-	3,796,806,131
<b>Total</b>	<b>\$ 12,687,082,953</b>	<b>\$ 9,719,220,076</b>	<b>\$ 22,406,303,029</b>	<b>\$ 226,600,000</b>	<b>\$ 22,632,903,029</b>

Notes: (a) See Exhibit 6.

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### SUMMARY OF OUTSTANDING LIABILITIES SEPARATING OUT PAYMENTS ON DOJ RECA SECTION 5 - DISCOUNTED

Fiscal Year	Part B Excluding Payments on Behalf of DOJ on RECA			Payments on Behalf of DOJ on RECA	
	Claims (a)	Part E (a)	(2) + (3)	Claims (a)	(4) + (5)
(1)	(2)	(3)	(4)	(5)	(6)
10/11 - 9/12	\$ 805,916,530	\$ 421,426,878	\$ 1,227,343,408	\$ 28,531,469	\$ 1,255,874,877
10/12 - 9/13	762,151,010	401,779,046	1,163,930,057	23,845,912	1,187,775,969
10/13 - 9/14	718,993,035	382,399,107	1,101,392,142	20,205,079	1,121,597,221
10/14 - 9/15	676,329,679	363,319,713	1,039,649,392	17,332,892	1,056,982,284
10/15 - 9/16	633,645,375	344,572,741	978,218,116	14,903,911	993,122,027
10/16 - 9/17	591,507,505	326,189,421	917,696,926	12,797,927	930,494,853
10/17 - 9/18	550,021,214	308,200,334	858,221,548	11,219,482	869,441,030
10/18 - 9/19	509,033,840	290,635,235	799,669,075	9,669,643	809,338,717
10/19 - 9/20	468,665,690	273,522,726	742,188,417	8,365,949	750,554,366
10/20 - 9/21	428,995,637	256,889,788	685,885,425	7,217,402	693,102,827
10/21 - 9/22	390,204,014	240,761,217	630,965,231	6,145,212	637,110,443
10/22 - 9/23	352,365,032	225,159,047	577,524,079	5,272,229	582,796,308
10/23 - 9/24	315,467,734	210,101,995	525,569,728	4,396,539	529,966,268
10/24 - 9/25	279,526,502	195,605,022	475,131,524	3,580,722	478,712,245
10/25 - 9/26	244,649,844	181,679,045	426,328,888	2,877,883	429,206,771
10/26 - 9/27	210,877,887	168,330,808	379,208,696	2,224,073	381,432,769
10/27 - 9/28	178,694,320	155,562,922	334,257,241	1,616,550	335,873,792
10/28 - 9/29	147,718,757	143,373,704	291,092,460	1,052,711	292,145,171
10/29 - 9/30	118,060,601	131,754,984	249,815,584	530,084	250,345,669
10/30 - 9/31	90,657,807	120,693,556	211,351,363	92,650	211,444,013
After 9/31	471,071,028	877,388,705	1,348,459,733	-	1,348,459,733
<b>Total</b>	<b>\$ 8,944,553,040</b>	<b>\$ 6,019,345,993</b>	<b>\$ 14,963,899,033</b>	<b>\$ 181,878,318</b>	<b>\$ 15,145,777,352</b>

Notes: (a) Based on Sheet 2 and the discount factors shown on Sheet 1.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**DERIVATION OF ESTIMATED ANNUAL MEDICAL PAYMENTS**

Category	Average Quarterly Medical Cost (a)	Fiscal Year	Escalated Annual Med Payments		Medical Inflation
			PART B (d)	PART E (d)	Rate (c)
RECA	3,369				
CN-SEC	3,175				
CN-NONSEC	1,613				
BD, CS, and BS	1,626	10/11 - 9/12	\$ 16,000	\$ 6,400	1.5%
		10/12 - 9/13	16,240	6,496	1.5%
ALL PART B	2,796	10/13 - 9/14	16,484	6,593	1.5%
		10/14 - 9/15	16,731	6,692	1.5%
PART E	1,334	10/15 - 9/16	16,982	6,793	1.5%
		10/16 - 9/17	17,237	6,895	1.5%
TOTAL PART B AND E	2,406	10/17 - 9/18	17,495	6,998	1.5%
		10/18 - 9/19	17,758	7,103	1.5%
		10/19 - 9/20	18,024	7,210	1.5%
		10/20 - 9/21	18,294	7,318	1.5%
Part B Selected Quarterly Payment (b)	4,000	10/21 - 9/22	18,569	7,427	1.5%
<b>Part B Selected Annual Payment</b>	<b>16,000</b>	10/22 - 9/23	18,847	7,539	1.5%
		10/23 - 9/24	19,130	7,652	1.5%
Part E Selected Quarterly Payment (b)	1,600	10/24 - 9/25	19,417	7,767	1.5%
<b>Part E Selected Annual Payment</b>	<b>6,400</b>	10/25 - 9/26	19,708	7,883	1.5%
		10/26 - 9/27	20,004	8,001	1.5%
		10/27 - 9/28	20,304	8,122	1.5%
		10/28 - 9/29	20,608	8,243	1.5%
		10/29 - 9/30	20,917	8,367	1.5%
		10/30 - 9/31	21,231	8,492	1.5%
		10/31 - 9/32	21,550	8,620	1.5%
		10/32 - 9/33	21,873	8,749	1.5%
		10/33 - 9/34	22,201	8,880	1.5%
		10/34 - 9/35	22,534	9,014	1.5%
		10/35 - 9/36	22,872	9,149	1.5%
		10/36 - 9/37	23,215	9,286	1.5%
		10/37 - 9/38	23,563	9,425	1.5%
		10/38 - 9/39	23,917	9,567	1.5%
		10/39 - 9/40	24,276	9,710	1.5%
		10/40 - 9/41	24,640	9,856	1.5%
		10/41 - 9/42	25,009	10,004	1.5%
		10/42 - 9/43	25,384	10,154	1.5%
		10/43 - 9/44	25,765	10,306	1.5%
		10/44 - 9/45	26,152	10,461	1.5%

- Notes: (a) See Sheet 2 through 8.  
 (b) Based on judgement.  
 (c) Based on a review of historical data and judgement.  
 (d) Selected annual payment times medical inflation rate.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**PART B AND E COMBINED (a)**

Paid Qtr	Cases Eligible	Cumulative	Actual Medical Paid	Medical Trend	Curr. Level Medical Paid	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	52	52	\$ -		\$ -	\$ -
4Q 2001	406	458	2,153		3,088	7
1Q 2002	355	813	302,794		429,235	528
2Q 2002	339	1,152	1,537,000		2,153,950	1,870
3Q 2002	324	1,476	1,980,454		2,743,721	1,859
4Q 2002	272	1,748	1,743,499		2,387,867	1,366
1Q 2003	237	1,985	3,435,956		4,671,181	2,353
2Q 2003	178	2,163	4,332,400		5,846,533	2,703
3Q 2003	114	2,277	5,221,526		6,994,521	3,072
4Q 2003	149	2,426	4,178,941		5,556,707	2,290
1Q 2004	178	2,604	7,170,777		9,432,836	3,622
2Q 2004	158	2,762	6,443,155		8,384,933	3,036
3Q 2004	179	2,941	5,207,365		6,704,153	2,280
4Q 2004	146	3,087	6,832,370		8,702,061	2,819
1Q 2005	194	3,281	7,930,535		9,997,381	3,047
2Q 2005	245	3,526	9,065,376		11,311,044	3,208
3Q 2005	256	3,782	8,946,708		11,048,751	2,921
4Q 2005	240	4,022	7,854,074		9,600,151	2,387
1Q 2006	327	4,349	11,328,793		13,712,237	3,153
2Q 2006	384	4,733	12,147,325		14,559,518	3,076
3Q 2006	475	5,208	10,199,062		12,105,097	2,324
4Q 2006	472	5,680	9,327,224		10,962,310	1,930
1Q 2007	693	6,373	13,352,596		15,525,308	2,436
2Q 2007	1,133	7,506	17,298,643		19,898,094	2,651
3Q 2007	1,433	8,939	20,296,328		23,096,266	2,584
4Q 2007	1,306	10,245	16,804,591		18,918,082	1,847
1Q 2008	1,032	11,277	17,791,010		19,847,466	1,760
2Q 2008	1,397	12,674	19,495,238		21,552,037	1,700
3Q 2008	1,636	14,310	23,265,421		25,487,428	1,781
4Q 2008	1,423	15,733	26,846,557		29,144,661	1,852
1Q 2009	1,238	16,971	26,169,903		28,173,602	1,660
2Q 2009	1,344	18,315	30,696,081		32,771,255	1,789
3Q 2009	1,344	19,659	36,648,555		38,800,459	1,974
4Q 2009	1,163	20,822	46,404,727		48,720,542	2,340
1Q 2010	1,052	21,874	45,626,952		47,505,206	2,172
2Q 2010	1,159	23,033	53,378,785		55,113,537	2,393
3Q 2010	1,364	24,397	72,140,914		73,865,409	3,028
4Q 2010	880	25,277	70,360,829		71,443,099	2,826
1Q 2011	1,105	26,382	81,826,264		82,453,176	3,125
2Q 2011	1,359	27,741	85,505,602		85,505,601	3,082
	27,741	372,053	\$ 829,096,483		\$ 895,128,503	\$ 2,406

Notes: (a) Sum of Sheets 3 and 8.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**ALL PART B (a)**

Paid Qtr	Cases Eligible	Cumulative	Actual Medical Paid	Medical Trend	Curr. Level Medical Paid	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	52	52	\$ -		\$ -	\$ -
4Q 2001	406	458	2,153		3,088	7
1Q 2002	355	813	302,794		429,235	528
2Q 2002	339	1,152	1,537,000		2,153,950	1,870
3Q 2002	324	1,476	1,980,454		2,743,721	1,859
4Q 2002	272	1,748	1,743,049		2,387,251	1,366
1Q 2003	237	1,985	3,432,367		4,666,303	2,351
2Q 2003	178	2,163	4,330,555		5,844,043	2,702
3Q 2003	114	2,277	5,215,506		6,986,457	3,068
4Q 2003	149	2,426	4,176,146		5,552,991	2,289
1Q 2004	178	2,604	7,167,510		9,428,538	3,621
2Q 2004	158	2,762	6,437,050		8,376,988	3,033
3Q 2004	179	2,941	5,201,030		6,695,997	2,277
4Q 2004	146	3,087	6,827,885		8,696,349	2,817
1Q 2005	194	3,281	7,922,890		9,987,744	3,044
2Q 2005	245	3,526	9,011,972		11,244,411	3,189
3Q 2005	254	3,780	8,836,200		10,912,279	2,887
4Q 2005	233	4,013	7,693,296		9,403,629	2,343
1Q 2006	309	4,322	10,656,340		12,898,307	2,984
2Q 2006	342	4,664	11,600,728		13,904,378	2,981
3Q 2006	405	5,069	9,651,102		11,454,732	2,260
4Q 2006	356	5,425	8,637,831		10,152,065	1,871
1Q 2007	488	5,913	12,318,218		14,322,618	2,422
2Q 2007	734	6,647	15,956,602		18,354,385	2,761
3Q 2007	844	7,491	18,752,334		21,339,273	2,849
4Q 2007	738	8,229	15,562,748		17,520,054	2,129
1Q 2008	584	8,813	16,178,450		18,048,511	2,048
2Q 2008	704	9,517	17,675,786		19,540,628	2,053
3Q 2008	902	10,419	19,720,229		21,603,645	2,073
4Q 2008	757	11,176	23,382,112		25,383,654	2,271
1Q 2009	616	11,792	21,959,479		23,640,807	2,005
2Q 2009	633	12,425	25,071,023		26,765,921	2,154
3Q 2009	644	13,069	30,162,780		31,933,857	2,443
4Q 2009	490	13,559	37,297,334		39,158,647	2,888
1Q 2010	527	14,086	36,375,204		37,872,606	2,689
2Q 2010	579	14,665	41,870,971		43,231,731	2,948
3Q 2010	738	15,403	55,635,117		56,965,049	3,698
4Q 2010	480	15,883	56,392,361		57,259,772	3,605
1Q 2011	581	16,464	67,338,335		67,854,247	4,121
2Q 2011	721	17,185	67,914,855		67,914,855	3,952
	17,185	272,760	\$ 701,927,795		\$ 762,632,716	\$ 2,796

Notes: (a) Sum of Sheets 4 through 7.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**PART B - RECA**

Paid Qtr	Cases Eligible (a)	Cumulative	Actual Medical Paid (b)	Medical Trend (c)	Curr. Level Medical Paid (d)	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	38	38	\$ -	1.450	\$ -	\$ -
4Q 2001	296	334	800	1.434	1,147	3
1Q 2002	102	436	82,905	1.418	117,525	270
2Q 2002	78	514	86,451	1.401	121,153	236
3Q 2002	108	622	186,833	1.385	258,838	416
4Q 2002	88	710	202,580	1.370	277,450	391
1Q 2003	74	784	392,775	1.359	533,977	681
2Q 2003	37	821	734,041	1.349	990,581	1,207
3Q 2003	33	854	1,091,672	1.340	1,462,355	1,712
4Q 2003	46	900	949,669	1.330	1,262,768	1,403
1Q 2004	60	960	1,259,991	1.315	1,657,462	1,727
2Q 2004	73	1,033	1,260,621	1.301	1,640,535	1,588
3Q 2004	71	1,104	1,250,904	1.287	1,610,459	1,459
4Q 2004	35	1,139	2,833,199	1.274	3,608,509	3,168
1Q 2005	99	1,238	3,924,156	1.261	4,946,865	3,996
2Q 2005	100	1,338	4,216,388	1.248	5,260,868	3,932
3Q 2005	76	1,414	3,699,132	1.235	4,568,249	3,231
4Q 2005	55	1,469	2,426,083	1.222	2,965,437	2,019
1Q 2006	74	1,543	5,142,580	1.210	6,224,518	4,034
2Q 2006	43	1,586	5,003,840	1.199	5,997,493	3,782
3Q 2006	92	1,678	3,704,340	1.187	4,396,619	2,620
4Q 2006	81	1,759	3,076,681	1.175	3,616,031	2,056
1Q 2007	169	1,928	4,567,892	1.163	5,311,171	2,755
2Q 2007	308	2,236	6,701,798	1.150	7,708,871	3,448
3Q 2007	351	2,587	6,658,525	1.138	7,577,088	2,929
4Q 2007	263	2,850	5,675,959	1.126	6,389,817	2,242
1Q 2008	243	3,093	5,858,562	1.116	6,535,752	2,113
2Q 2008	230	3,323	6,542,731	1.106	7,233,006	2,177
3Q 2008	330	3,653	6,771,538	1.096	7,418,266	2,031
4Q 2008	265	3,918	8,788,225	1.086	9,540,509	2,435
1Q 2009	254	4,172	8,130,603	1.077	8,753,123	2,098
2Q 2009	236	4,408	8,697,989	1.068	9,286,007	2,107
3Q 2009	233	4,641	12,118,512	1.059	12,830,078	2,765
4Q 2009	144	4,785	16,672,558	1.050	17,504,597	3,658
1Q 2010	143	4,928	14,908,943	1.041	15,522,676	3,150
2Q 2010	126	5,054	18,013,046	1.032	18,598,450	3,680
3Q 2010	136	5,190	26,282,566	1.024	26,910,838	5,185
4Q 2010	104	5,294	28,383,718	1.015	28,820,308	5,444
1Q 2011	127	5,421	37,315,659	1.008	37,601,553	6,936
2Q 2011	154	5,575	36,133,650	1.000	36,133,650	6,481
	5,575	95,330	\$ 299,748,111		\$ 321,194,599	\$ 3,369

Notes: (a) Eligible cases are all cases with a living employee whether they have received medical benefits or not.  
(b) See Exhibit 3, Table 9.  
(c) Based on historical CPI indices for medical care services.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**PART B - CN-SEC**

Paid Qtr	Cases Eligible (a)	Cumulative	Actual Medical Paid (b)	Medical Trend (c)	Curr. Level Medical Paid (d)	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	14	14	\$ -	1.450	\$ -	\$ -
4Q 2001	84	98	1,354	1.434	1,941	20
1Q 2002	182	280	217,818	1.418	308,775	1,103
2Q 2002	121	401	1,417,413	1.401	1,986,361	4,954
3Q 2002	134	535	1,654,488	1.385	2,292,127	4,284
4Q 2002	106	641	1,297,136	1.370	1,776,535	2,772
1Q 2003	97	738	2,076,125	1.359	2,822,491	3,825
2Q 2003	97	835	2,420,146	1.349	3,265,964	3,911
3Q 2003	41	876	3,178,753	1.340	4,258,114	4,861
4Q 2003	44	920	2,608,193	1.330	3,468,094	3,770
1Q 2004	44	964	4,594,394	1.315	6,043,720	6,269
2Q 2004	32	996	4,100,574	1.301	5,336,366	5,358
3Q 2004	49	1,045	3,076,747	1.287	3,961,116	3,791
4Q 2004	39	1,084	3,001,144	1.274	3,822,412	3,526
1Q 2005	16	1,100	3,136,840	1.261	3,954,360	3,595
2Q 2005	44	1,144	3,434,435	1.248	4,285,211	3,746
3Q 2005	75	1,219	3,500,014	1.235	4,322,348	3,546
4Q 2005	98	1,317	3,772,931	1.222	4,611,708	3,502
1Q 2006	98	1,415	4,091,277	1.210	4,952,033	3,500
2Q 2006	117	1,532	4,161,217	1.199	4,987,543	3,256
3Q 2006	139	1,671	3,828,325	1.187	4,543,775	2,719
4Q 2006	132	1,803	3,694,115	1.175	4,341,703	2,408
1Q 2007	177	1,980	5,181,311	1.163	6,024,405	3,043
2Q 2007	222	2,202	6,525,123	1.150	7,505,646	3,409
3Q 2007	298	2,500	8,583,775	1.138	9,767,932	3,907
4Q 2007	304	2,804	7,121,325	1.126	8,016,965	2,859
1Q 2008	213	3,017	7,014,517	1.116	7,825,322	2,594
2Q 2008	288	3,305	7,773,347	1.106	8,593,456	2,600
3Q 2008	347	3,652	8,619,091	1.096	9,442,273	2,586
4Q 2008	328	3,980	10,569,627	1.086	11,474,402	2,883
1Q 2009	250	4,230	9,058,690	1.077	9,752,268	2,306
2Q 2009	246	4,476	11,258,232	1.068	12,019,332	2,685
3Q 2009	252	4,728	12,624,873	1.059	13,366,171	2,827
4Q 2009	213	4,941	14,619,912	1.050	15,349,514	3,107
1Q 2010	247	5,188	15,984,193	1.041	16,642,189	3,208
2Q 2010	343	5,531	16,700,066	1.032	17,242,800	3,117
3Q 2010	470	6,001	20,756,291	1.024	21,252,461	3,541
4Q 2010	270	6,271	20,204,960	1.015	20,515,747	3,272
1Q 2011	354	6,625	20,981,056	1.008	21,141,802	3,191
2Q 2011	443	7,068	23,429,095	1.000	23,429,095	3,315
	7,068	99,127	\$ 286,268,918		\$ 314,704,477	\$ 3,175

Notes: (a) Eligible cases are all cases with a living employee whether they have received medical benefits or not.  
(b) See Exhibit 3, Table 9.  
(c) Based on historical CPI indices for medical care services.



**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**PART B - CN-NONSEC**

Paid Qtr	Cases Eligible (a)	Cumulative	Actual Medical Paid (b)	Medical Trend (c)	Curr. Level Medical Paid (d)	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	-	-	\$ -	1.450	\$ -	\$ -
4Q 2001	-	-	-	1.434	-	-
1Q 2002	-	-	-	1.418	-	-
2Q 2002	-	-	-	1.401	-	-
3Q 2002	-	-	1,371	1.385	1,900	-
4Q 2002	1	1	3,694	1.370	5,059	5,059
1Q 2003	-	1	28,057	1.359	38,143	38,143
2Q 2003	8	9	25,305	1.349	34,149	3,794
3Q 2003	9	18	33,726	1.340	45,178	2,510
4Q 2003	39	57	44,421	1.330	59,066	1,036
1Q 2004	35	92	166,743	1.315	219,343	2,384
2Q 2004	24	116	124,568	1.301	162,110	1,398
3Q 2004	30	146	191,368	1.287	246,374	1,687
4Q 2004	57	203	251,286	1.274	320,051	1,577
1Q 2005	54	257	266,503	1.261	335,959	1,307
2Q 2005	77	334	396,166	1.248	494,304	1,480
3Q 2005	97	431	540,462	1.235	667,444	1,549
4Q 2005	67	498	556,842	1.222	680,636	1,367
1Q 2006	112	610	583,048	1.210	705,714	1,157
2Q 2006	147	757	1,497,139	1.199	1,794,438	2,370
3Q 2006	148	905	1,025,957	1.187	1,217,692	1,346
4Q 2006	120	1,025	960,397	1.175	1,128,757	1,101
1Q 2007	112	1,137	1,579,038	1.163	1,835,977	1,615
2Q 2007	163	1,300	1,674,664	1.150	1,926,314	1,482
3Q 2007	148	1,448	2,228,949	1.138	2,536,439	1,752
4Q 2007	125	1,573	1,359,998	1.126	1,531,043	973
1Q 2008	103	1,676	1,725,985	1.116	1,925,491	1,149
2Q 2008	141	1,817	1,887,968	1.106	2,087,153	1,149
3Q 2008	178	1,995	2,940,702	1.096	3,221,559	1,615
4Q 2008	109	2,104	2,775,374	1.086	3,012,950	1,432
1Q 2009	63	2,167	2,853,257	1.077	3,071,717	1,417
2Q 2009	103	2,270	3,438,904	1.068	3,671,387	1,617
3Q 2009	110	2,380	3,293,384	1.059	3,486,763	1,465
4Q 2009	88	2,468	3,984,272	1.050	4,183,106	1,695
1Q 2010	91	2,559	3,661,849	1.041	3,812,591	1,490
2Q 2010	78	2,637	4,160,783	1.032	4,296,003	1,629
3Q 2010	76	2,713	5,316,494	1.024	5,443,582	2,006
4Q 2010	69	2,782	5,112,599	1.015	5,191,240	1,866
1Q 2011	66	2,848	6,460,460	1.008	6,509,956	2,286
2Q 2011	92	2,940	5,504,432	1.000	5,504,432	1,872
	2,940	44,274	\$ 66,656,165		\$ 71,404,020	\$ 1,613

Notes: (a) Eligible cases are all cases with a living employee whether they have received medical benefits or not.  
(b) See Exhibit 3, Table 9.  
(c) Based on historical CPI indices for medical care services.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**PART B - BD, CS, AND BS**

Paid Qtr	Cases Eligible (a)	Cumulative	Actual Medical Paid (b)	Medical Trend (c)	Curr. Level Medical Paid (d)	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	-	-	\$ -	1.450	\$ -	\$ -
4Q 2001	26	26	-	1.434	-	-
1Q 2002	71	97	2,070	1.418	2,935	30
2Q 2002	140	237	33,136	1.401	46,436	196
3Q 2002	82	319	137,762	1.385	190,856	598
4Q 2002	77	396	239,640	1.370	328,207	829
1Q 2003	66	462	935,412	1.359	1,271,692	2,753
2Q 2003	36	498	1,151,063	1.349	1,553,349	3,119
3Q 2003	31	529	911,355	1.340	1,220,810	2,308
4Q 2003	20	549	573,864	1.330	763,063	1,390
1Q 2004	39	588	1,146,381	1.315	1,508,013	2,565
2Q 2004	29	617	951,287	1.301	1,237,977	2,006
3Q 2004	29	646	682,013	1.287	878,048	1,359
4Q 2004	15	661	742,257	1.274	945,377	1,430
1Q 2005	25	686	595,390	1.261	750,560	1,094
2Q 2005	24	710	964,983	1.248	1,204,028	1,696
3Q 2005	6	716	1,096,592	1.235	1,354,238	1,891
4Q 2005	13	729	937,441	1.222	1,145,848	1,572
1Q 2006	25	754	839,435	1.210	1,016,042	1,348
2Q 2006	35	789	938,532	1.199	1,124,904	1,426
3Q 2006	26	815	1,092,480	1.187	1,296,646	1,591
4Q 2006	23	838	906,638	1.175	1,065,574	1,272
1Q 2007	30	868	989,977	1.163	1,151,065	1,326
2Q 2007	41	909	1,055,017	1.150	1,213,554	1,335
3Q 2007	47	956	1,281,084	1.138	1,457,814	1,525
4Q 2007	46	1,002	1,405,466	1.126	1,582,229	1,579
1Q 2008	25	1,027	1,579,385	1.116	1,761,946	1,716
2Q 2008	45	1,072	1,471,740	1.106	1,627,013	1,518
3Q 2008	47	1,119	1,388,898	1.096	1,521,547	1,360
4Q 2008	55	1,174	1,248,887	1.086	1,355,793	1,155
1Q 2009	49	1,223	1,916,929	1.077	2,063,699	1,687
2Q 2009	48	1,271	1,675,898	1.068	1,789,195	1,408
3Q 2009	49	1,320	2,126,012	1.059	2,250,845	1,705
4Q 2009	45	1,365	2,020,593	1.050	2,121,430	1,554
1Q 2010	46	1,411	1,820,220	1.041	1,895,150	1,343
2Q 2010	32	1,443	2,997,076	1.032	3,094,478	2,144
3Q 2010	56	1,499	3,279,767	1.024	3,358,168	2,240
4Q 2010	37	1,536	2,691,084	1.015	2,732,477	1,779
1Q 2011	34	1,570	2,581,160	1.008	2,600,936	1,657
2Q 2011	32	1,602	2,847,678	1.000	2,847,678	1,778
	1,602	34,029	\$ 49,254,601		\$ 55,329,620	\$ 1,626

Notes: (a) Eligible cases are all cases with a living employee whether they have received medical benefits or not.  
(b) See Exhibit 3, Table 9.  
(c) Based on historical CPI indices for medical care services.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**SUMMARY OF AVERAGE QUARTERLY MEDICAL PAYMENTS**

**PART E**

Paid Qtr	Cases Eligible (a)	Cumulative	Actual Medical Paid (b)	Medical Trend (c)	Curr. Level Medical Paid (d)	Average [ (6) ÷ (3) ]
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3Q 2001	-	-	\$ -	1.450	\$ -	\$ -
4Q 2001	-	-	-	1.434	-	-
1Q 2002	-	-	-	1.418	-	-
2Q 2002	-	-	-	1.401	-	-
3Q 2002	-	-	-	1.385	-	-
4Q 2002	-	-	450	1.370	616	-
1Q 2003	-	-	3,588	1.359	4,878	-
2Q 2003	-	-	1,845	1.349	2,490	-
3Q 2003	-	-	6,020	1.340	8,064	-
4Q 2003	-	-	2,795	1.330	3,716	-
1Q 2004	-	-	3,268	1.315	4,298	-
2Q 2004	-	-	6,105	1.301	7,945	-
3Q 2004	-	-	6,335	1.287	8,156	-
4Q 2004	-	-	4,485	1.274	5,712	-
1Q 2005	-	-	7,645	1.261	9,637	-
2Q 2005	-	-	53,404	1.248	66,633	-
3Q 2005	2	2	110,508	1.235	136,472	68,236
4Q 2005	7	9	160,778	1.222	196,522	21,836
1Q 2006	18	27	672,453	1.210	813,930	30,146
2Q 2006	42	69	546,597	1.199	655,140	9,495
3Q 2006	70	139	547,960	1.187	650,365	4,679
4Q 2006	116	255	689,392	1.175	810,245	3,177
1Q 2007	205	460	1,034,378	1.163	1,202,690	2,615
2Q 2007	399	859	1,342,042	1.150	1,543,709	1,797
3Q 2007	589	1,448	1,543,995	1.138	1,756,993	1,213
4Q 2007	568	2,016	1,241,843	1.126	1,398,028	693
1Q 2008	448	2,464	1,612,560	1.116	1,798,955	730
2Q 2008	693	3,157	1,819,452	1.106	2,011,409	637
3Q 2008	734	3,891	3,545,193	1.096	3,883,783	998
4Q 2008	666	4,557	3,464,445	1.086	3,761,007	825
1Q 2009	622	5,179	4,210,424	1.077	4,532,795	875
2Q 2009	711	5,890	5,625,058	1.068	6,005,334	1,020
3Q 2009	700	6,590	6,485,774	1.059	6,866,602	1,042
4Q 2009	673	7,263	9,107,393	1.050	9,561,895	1,317
1Q 2010	525	7,788	9,251,748	1.041	9,632,600	1,237
2Q 2010	580	8,368	11,507,814	1.032	11,881,806	1,420
3Q 2010	626	8,994	16,505,796	1.024	16,900,360	1,879
4Q 2010	400	9,394	13,968,468	1.015	14,183,327	1,510
1Q 2011	524	9,918	14,487,930	1.008	14,598,929	1,472
2Q 2011	638	10,556	17,590,746	1.000	17,590,746	1,666
	10,556	99,293	\$ 127,168,688		\$ 132,495,787	\$ 1,334

Notes: (a) Eligible cases are all cases with a living employee whether they have received medical benefits or not.  
(b) See Exhibit 3, Table 9.  
(c) Based on historical CPI indices for medical care services.

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

**TABLE 1 - NUMBER OF CASES AND CLAIMS BY DISEASE**

Disease	Number of Cases	Number of Claims
(1)	(2)	(3)
RECA	7,804	12,715
BD	3,681	5,511
CS	488	700
CN-SEC	29,973	51,917
CN-NONSEC	25,190	36,422
BS	1,886	1,908
OL	2,637	3,089
RN	387	485
OTHER, UNKNOWN	3,444	3,945
99	1,960	2,186
PART B SUBTOTAL	77,450	118,878
PART E - WITH PART B CLAIM	59,743	88,230
PART E - ONLY	8,320	9,262
PART E SUBTOTAL	68,063	97,492
TOTAL	145,513	216,370

Note: Total number of cases includes cases double counted as Part B and Part E.  
The total number of cases is 85,770.

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

**TABLE 2 - CASES FILED BY DISEASE**

Disease	Number of Cases Filed by: (a)				Actual	Selected
	Employer	Survivor	Both	Total	Emp/Both Percentage (b)	Percentage
(1)	(2)	(3)	(4)	(5)	(6)	(7)
RECA	4,025	3,493	286	7,804	55.2%	55.0%
BD	1,889	1,522	270	3,681	58.7%	58.0%
CS	319	135	34	488	72.3%	73.0%
CN-SEC	12,411	14,624	2,938	29,973	51.2%	50.0%
CN-NONSEC	12,323	10,886	1,981	25,190	56.8%	56.0%
BS	1,852	26	8	1,886	98.6%	99.0%
PART E	36,516	26,646	4,901	68,063	60.9%	60.0%
TOTAL	69,335	57,332	10,418	137,085	58.2%	

Note: (a) Based on data provided by DOL.

(b) [ {(2) + (4)} ÷ (5) ]

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

**TABLE 3 - AVERAGE AGE OF EMPLOYEE AT TIME CLAIM IS FILED (a)**

Year of Claim Filing (b)	PART B		PART E	
	Average Age	Number of Cases	Average Age	Number of Cases
(1)	(2)	(3)	(4)	(5)
2001	67	8,790	66	2,569
2002	66	7,880	66	5,246
2003	65	4,894	65	4,621
2004	68	3,949	67	3,113
2005	68	3,437	68	5,751
2006	68	2,834	67	4,001
2007	68	3,165	68	3,984
2008	69	2,543	68	3,280
2009	69	2,506	67	3,247
2010	70	3,067	68	3,678
2011	69	1,324	68	1,535

Notes: (a) For employee filed cases only  
(b) 2011 data through June 30 only.

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

**TABLE 4 - SEX OF EMPLOYEE**

Category	Male	Female	Blank	Total	Male Percentage (a)
(1)	(2)	(3)	(4)	(5)	(6)
RECA	7,583	156	11	7,750	97.8%
BD	2,986	406	2	3,394	88.0%
CS	411	16	3	430	95.6%
CN-SEC	24,611	3,813	58	28,482	86.4%
CN-NONSEC	20,672	3,017	20	23,709	87.2%
BS	1,423	387	2	1,812	78.5%
PART E	10,361	1,760	269	12,390	83.6%

Notes: (a) [ (2) ÷ (5) ]

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**TABLE 5 - ACTUAL CASES APPROVED BY QUARTER**

App. Quarter (1)	RECA (2)	BD (3)	CS (4)	CN-SEC (5)	CN Non SEC (6)	BS (7)	OL (8)	RN (9)	Other (10)	99 (11)	Blank (12)	Part B Subtotal (13)	Part E (14)	Total (15)
No Date	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pre 3Q 2001	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3Q 2001	139	2	1	37	-	-	-	-	-	-	-	-	-	-
4Q 2001	746	28	6	160	-	-	-	-	-	-	-	179	-	179
1Q 2002	391	93	6	417	3	8	-	-	-	-	-	940	-	940
2Q 2002	316	172	4	323	7	35	1	-	-	-	-	918	-	918
3Q 2002	275	119	7	422	11	71	-	-	-	-	-	858	-	858
4Q 2002	319	110	4	325	14	141	1	-	-	-	-	905	-	905
1Q 2003	195	112	2	408	14	116	-	-	-	-	-	847	-	847
2Q 2003	105	80	1	311	43	311	-	-	-	-	-	588	-	588
3Q 2003	116	64	2	177	97	42	-	-	-	-	-	498	-	498
4Q 2003	130	68	2	178	137	25	-	1	-	-	-	541	-	541
1Q 2004	143	82	1	158	108	29	-	1	-	-	-	522	-	522
2Q 2004	169	55	2	167	117	26	-	2	-	-	-	538	-	538
3Q 2004	142	63	5	184	122	20	-	-	-	-	-	536	-	536
4Q 2004	95	49	2	176	165	17	2	5	-	-	-	511	2	513
1Q 2005	196	53	2	164	159	8	-	4	-	-	-	586	323	909
2Q 2005	171	47	1	177	233	17	-	14	-	-	-	660	383	1,043
3Q 2005	133	34	1	359	313	12	-	13	-	-	-	865	1,217	2,082
4Q 2005	118	39	1	306	237	12	-	8	-	-	-	721	443	1,164
1Q 2006	111	38	1	377	295	12	1	10	-	1	-	846	732	1,578
2Q 2006	100	45	4	385	339	10	-	17	-	-	-	900	1,746	2,646
3Q 2006	141	42	1	338	357	9	1	15	-	-	-	904	1,245	2,149
4Q 2006	169	35	4	395	290	18	1	16	-	-	-	928	992	1,920
1Q 2007	245	46	1	337	258	23	2	12	-	1	-	925	968	1,893
2Q 2007	315	28	2	494	284	32	-	7	-	-	-	1,162	1,308	2,470
3Q 2007	378	35	1	437	152	32	-	2	-	-	-	1,037	1,205	2,242
4Q 2007	221	24	4	613	151	34	1	1	-	-	-	1,050	1,075	2,125
1Q 2008	172	24	2	524	152	31	-	3	-	-	-	908	812	1,720
2Q 2008	106	33	2	583	193	20	-	-	-	-	-	937	915	1,852
3Q 2008	158	32	3	674	201	13	-	5	-	-	-	1,086	963	2,049
4Q 2008	145	33	2	836	139	25	-	3	-	-	-	1,183	977	2,160
1Q 2009	130	32	1	471	120	9	-	1	-	-	-	764	698	1,462
2Q 2009	91	23	1	476	121	16	-	2	-	-	-	730	690	1,420
3Q 2009	96	22	1	382	119	15	-	1	-	-	-	636	608	1,244
4Q 2009	85	22	1	341	98	16	-	1	-	-	-	564	538	1,102
1Q 2010	84	20	2	593	88	16	-	1	-	-	-	804	593	1,397
2Q 2010	86	21	2	736	82	12	-	1	-	1	-	941	530	1,471
3Q 2010	80	21	-	1,138	105	8	-	4	-	-	-	1,356	670	2,026
4Q 2010	70	10	-	1,188	83	14	-	2	-	-	-	1,366	514	1,880
1Q 2011	73	7	-	822	70	18	-	2	-	-	-	992	364	1,356
2Q 2011	84	11	-	788	78	14	-	1	-	-	-	976	268	1,244
	7,039	1,874	85	17,377	5,555	1,024	10	1	154	3	-	33,122	20,779	53,901



**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**TABLE 6 - COMPENSATION ACTUAL DOLLARS PAID BY QUARTER**

Paid Qtr (1)	RECA (2)	BD (3)	CS (4)	CN-SEC (5)	CN Non SEC (6)	BS (7)	OL (8)	RN (9)	Other (10)	99 (11)	Blank (12)	Part E (13)	Total (14)	RECA Benefits Paid on Behalf of DOJ (15)
No Date	\$ 200,000	\$ -	\$ -	\$ 150,000	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 350,000	\$ -
3Q 2001	2,600,000	150,000	-	5,025,000	-	-	-	-	-	-	-	-	7,775,000	-
4Q 2001	34,330,000	3,900,000	150,000	23,625,000	-	-	-	-	-	-	-	-	62,005,000	-
1Q 2002	22,370,000	11,177,592	750,000	60,975,000	50,000	-	-	-	-	-	-	-	95,322,592	-
2Q 2002	18,055,714	24,922,035	1,200,000	54,028,422	-	-	50,000	-	-	-	-	-	98,256,171	-
3Q 2002	14,393,274	17,243,937	450,000	59,756,505	350,000	-	-	-	-	-	-	-	92,193,716	-
4Q 2002	14,297,004	16,283,333	150,000	53,378,929	850,000	-	-	-	-	-	-	-	84,959,266	-
1Q 2003	12,608,268	16,716,667	900,000	57,382,310	300,000	-	50,000	-	-	-	-	-	87,957,245	-
2Q 2003	6,424,962	10,621,872	600,000	54,048,750	4,300,000	-	-	-	-	-	-	-	75,995,585	-
3Q 2003	6,025,752	8,304,240	450,000	28,864,643	14,120,000	-	-	-	-	-	-	-	57,764,635	-
4Q 2003	6,048,712	8,315,000	150,000	28,832,857	19,790,714	-	-	150,000	-	-	-	-	63,287,283	-
1Q 2004	7,214,167	12,503,172	150,000	25,137,500	17,814,286	-	-	-	-	-	-	-	62,819,124	-
2Q 2004	8,562,500	9,547,500	150,000	24,564,643	17,252,500	-	-	-	450,000	-	-	-	60,527,143	-
3Q 2004	7,784,167	9,067,500	300,000	28,295,357	16,147,500	-	-	-	-	-	-	-	61,594,524	-
4Q 2004	4,818,333	7,087,500	150,000	25,869,167	26,355,000	-	225,000	-	450,000	-	-	125,000	65,080,000	-
1Q 2005	8,748,611	9,187,500	300,000	28,339,167	24,407,500	-	75,000	-	600,000	-	-	30,750,000	102,407,778	13,533,333
2Q 2005	9,594,949	6,900,000	650,000	25,455,000	33,638,571	-	-	-	2,200,000	-	-	38,000,000	116,438,521	20,818,171
3Q 2005	7,261,519	4,950,000	150,000	50,110,833	49,481,250	-	-	-	2,000,000	-	-	129,334,874	243,288,476	23,050,000
4Q 2005	5,824,169	5,010,000	150,000	50,160,000	34,496,012	-	-	-	900,000	-	-	71,213,898	167,754,079	16,916,667
1Q 2006	6,932,381	5,190,000	300,000	53,613,571	46,872,738	-	-	-	1,650,000	150,000	-	50,116,749	164,825,439	15,091,667
2Q 2006	5,133,095	7,500,000	150,000	57,942,738	52,258,526	-	150,000	-	2,425,000	-	-	77,226,620	202,785,979	13,633,333
3Q 2006	7,695,833	7,012,500	120,000	55,286,806	50,879,064	-	150,000	-	2,225,000	-	-	78,771,711	202,140,914	35,900,000
4Q 2006	6,113,036	4,837,500	150,000	42,340,000	42,182,857	-	-	-	1,650,000	-	-	64,417,778	161,691,171	19,625,000
1Q 2007	11,216,131	4,950,000	187,500	61,295,000	43,872,500	-	300,000	-	2,587,500	-	-	78,829,054	203,237,685	28,816,667
2Q 2007	16,650,000	4,256,250	217,500	62,278,869	41,607,500	-	150,000	-	1,087,500	-	-	100,848,005	227,095,624	17,780,000
3Q 2007	17,939,583	4,253,913	450,000	67,650,249	26,512,500	-	-	150,000	450,000	-	-	118,699,380	235,955,625	11,604,571
4Q 2007	13,591,488	3,697,500	575,000	82,575,714	21,226,429	-	-	-	375,000	-	-	112,855,517	235,196,648	11,844,286
1Q 2008	10,115,165	3,637,500	150,000	85,408,885	23,137,500	-	-	-	200,000	-	-	105,247,289	227,896,339	13,220,000
2Q 2008	5,507,930	3,075,000	300,000	74,534,264	26,537,500	-	-	-	203,571	-	-	121,307,164	231,465,430	11,900,000
3Q 2008	8,417,500	4,537,500	-	93,997,418	30,025,000	-	-	-	750,000	-	-	129,708,613	267,436,031	8,411,111
4Q 2008	6,997,500	4,800,000	150,000	126,314,969	19,475,000	-	-	-	300,000	-	-	126,836,035	284,873,504	11,505,000
1Q 2009	6,819,147	3,225,000	600,000	75,995,055	15,615,000	-	-	-	250,000	-	-	100,981,626	203,485,828	7,680,000
2Q 2009	5,085,556	2,850,000	300,000	65,981,685	17,362,500	-	-	-	200,000	-	-	103,436,383	195,216,123	8,742,424
3Q 2009	4,916,667	2,850,000	300,000	54,917,070	16,185,000	-	-	-	300,000	-	-	101,084,754	180,553,491	8,420,000
4Q 2009	4,595,455	2,100,000	-	42,541,479	13,600,000	150,000	-	-	50,000	-	-	91,616,856	154,503,789	8,850,000
1Q 2010	4,408,333	2,400,000	300,000	72,065,472	11,825,000	-	-	-	300,000	-	-	88,530,966	179,979,776	6,500,000
2Q 2010	4,366,667	2,400,000	200,000	99,364,702	11,017,500	-	-	-	150,000	-	-	90,707,851	208,206,720	8,866,234
3Q 2010	4,129,545	3,000,000	50,000	155,835,952	12,869,643	-	-	-	500,000	150,000	-	105,784,906	282,320,047	4,848,485
4Q 2010	4,213,333	1,425,000	281,250	175,399,505	12,650,000	-	-	-	150,000	-	-	83,657,483	277,776,572	9,118,889
1Q 2011	3,836,602	1,350,000	-	120,890,984	8,925,000	-	-	-	300,000	-	-	80,381,154	215,683,740	6,880,000
2Q 2011	3,850,101	1,709,539	50,000	108,145,989	9,650,000	-	-	-	150,000	-	-	87,391,407	210,947,036	6,405,397
	\$ 359,693,150	\$ 262,945,050	\$ 11,631,250	\$ 2,518,375,464	\$ 813,640,090	\$ 150,000	\$ 1,300,000	\$ 150,000	\$ 23,003,571	\$ 300,000	\$ -	\$ 2,367,861,073	\$ 6,359,049,647	\$ 351,761,234

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**TABLE 7 - NUMBER OF CASES PAID COMPENSATION BY QUARTER**

Paid Qtr (1)	RECA (2)	BD (3)	CS (4)	CN-SEC (5)	CN Non SEC (6)	BS (7)	OL (8)	RN (9)	Other (10)	99 (11)	Blank (12)	Part E (13)	Total (14)
No Date	4	-	-	1	-	-	-	-	-	-	-	-	5
3Q 2001	52	1	-	34	-	-	-	-	-	-	-	-	87
4Q 2001	685	26	1	158	-	-	-	-	-	-	-	-	870
1Q 2002	440	75	5	408	1	-	-	-	-	-	-	-	929
2Q 2002	366	169	8	363	-	-	1	-	-	-	-	-	907
3Q 2002	304	118	3	402	3	-	-	-	-	-	-	-	830
4Q 2002	307	110	1	363	7	-	-	-	-	-	-	-	788
1Q 2003	260	113	6	392	2	-	1	-	-	-	-	-	774
2Q 2003	138	71	4	372	30	-	-	-	-	-	-	-	615
3Q 2003	124	57	3	202	95	-	-	-	-	-	-	-	481
4Q 2003	123	58	1	198	134	-	-	-	1	-	-	-	515
1Q 2004	146	88	1	170	121	-	-	-	-	-	-	-	526
2Q 2004	165	65	1	172	117	-	-	-	3	-	-	-	523
3Q 2004	161	62	2	197	110	-	-	-	-	-	-	-	532
4Q 2004	95	49	1	180	180	-	2	-	3	-	-	1	511
1Q 2005	173	62	2	195	168	-	1	-	4	-	-	246	851
2Q 2005	188	46	5	180	232	-	-	-	15	-	-	304	970
3Q 2005	142	33	1	343	340	-	-	-	14	-	-	1,008	1,881
4Q 2005	118	34	1	342	239	-	-	-	6	-	-	562	1,302
1Q 2006	132	35	2	368	323	-	-	-	11	1	-	396	1,268
2Q 2006	101	50	1	402	358	-	1	-	17	-	-	618	1,548
3Q 2006	148	47	1	384	347	-	1	-	16	-	-	641	1,585
4Q 2006	123	33	1	295	291	-	-	-	11	-	-	557	1,311
1Q 2007	231	33	2	430	305	-	2	-	18	-	-	695	1,716
2Q 2007	338	30	3	449	291	-	1	-	8	-	-	935	2,055
3Q 2007	354	30	3	484	185	-	-	-	3	-	-	1,125	2,184
4Q 2007	269	26	5	581	152	-	-	1	3	-	-	1,108	2,146
1Q 2008	196	25	1	600	159	-	-	-	2	-	-	1,016	1,999
2Q 2008	117	21	2	531	182	-	-	-	2	-	-	1,216	2,071
3Q 2008	165	32	1	659	208	-	-	-	5	-	-	1,374	2,443
4Q 2008	137	33	1	901	139	-	-	-	2	-	-	1,361	2,574
1Q 2009	132	22	4	563	110	-	-	-	2	-	-	1,116	1,949
2Q 2009	99	19	2	487	121	-	-	-	2	-	-	1,232	1,962
3Q 2009	97	19	2	402	115	-	-	-	2	-	-	1,192	1,829
4Q 2009	89	14	-	308	93	-	-	-	1	-	-	1,102	1,607
1Q 2010	89	16	2	507	81	-	1	-	2	-	-	1,034	1,732
2Q 2010	86	16	2	689	77	-	-	-	1	-	-	1,061	1,932
3Q 2010	76	20	1	1,080	90	-	-	-	4	1	-	1,264	2,536
4Q 2010	80	10	2	1,229	86	-	-	-	2	-	-	992	2,400
1Q 2011	73	9	-	860	60	-	-	-	2	-	-	985	1,989
2Q 2011	78	12	1	773	65	-	-	-	1	-	-	1,134	2,064
	7,201	1,789	84	17,653	5,617	1	11	1	162	2	-	24,275	56,792

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**TABLE 8 - NUMBER OF PAID CASES BY LIVING EMPLOYEE (NOT SURVIVOR)**

Paid Qtr	RECA	BD	CS	CN-SEC	CN Non SEC	BS	OL	RN	Other	99	Blank	Part E	Total
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)
No Date	0	0	0	0	0	0	0	0	0	0	0	0	0
3Q 2001	37	0	0	14	0	0	0	0	0	0	0	0	51
4Q 2001	300	25	1	88	0	0	0	0	0	0	0	0	414
1Q 2002	111	69	3	191	0	0	0	0	0	0	0	0	374
2Q 2002	83	136	5	128	0	0	0	0	0	0	0	0	352
3Q 2002	112	80	3	147	0	0	0	0	0	0	0	0	342
4Q 2002	101	78	1	120	1	0	0	0	0	0	0	0	301
1Q 2003	86	64	5	120	0	0	0	0	0	0	0	0	275
2Q 2003	52	36	4	109	8	0	0	0	0	0	0	0	209
3Q 2003	41	31	1	58	10	0	0	0	0	0	0	0	141
4Q 2003	63	23	0	64	39	0	0	0	0	0	0	0	189
1Q 2004	81	41	1	63	35	0	0	0	0	0	0	0	221
2Q 2004	90	30	1	50	27	0	0	0	1	0	0	0	199
3Q 2004	80	28	2	62	31	0	0	0	0	0	0	0	203
4Q 2004	53	18	1	68	60	0	0	0	0	0	0	0	200
1Q 2005	110	27	2	49	57	0	0	0	0	0	0	0	245
2Q 2005	123	22	5	66	79	0	0	0	0	0	0	0	295
3Q 2005	98	17	0	100	98	0	0	0	1	0	0	2	316
4Q 2005	82	16	1	118	73	0	0	0	0	0	0	0	297
1Q 2006	95	21	2	113	120	0	0	0	2	0	0	18	371
2Q 2006	67	30	1	131	151	0	0	0	1	0	0	43	424
3Q 2006	108	21	0	133	150	0	0	0	1	0	0	71	484
4Q 2006	80	16	0	108	127	0	0	0	2	0	0	121	454
1Q 2007	156	16	1	113	111	0	0	0	0	0	0	219	616
2Q 2007	257	8	0	113	113	0	0	0	1	0	0	414	906
3Q 2007	238	14	2	140	73	0	0	0	0	0	0	614	1,081
4Q 2007	147	14	3	159	48	0	0	0	0	0	0	609	980
1Q 2008	114	12	0	159	67	0	0	0	0	0	0	521	873
2Q 2008	67	13	1	147	78	0	0	0	0	0	0	753	1,059
3Q 2008	103	20	0	211	86	0	0	0	0	0	0	809	1,229
4Q 2008	82	18	0	224	63	0	0	0	1	0	0	769	1,157
1Q 2009	76	17	2	141	49	0	0	0	0	0	0	694	979
2Q 2009	54	12	1	154	57	0	0	0	0	0	0	811	1,089
3Q 2009	61	16	2	132	57	0	0	0	0	0	0	814	1,082
4Q 2009	50	11	0	105	53	0	0	0	0	0	0	804	1,023
1Q 2010	59	13	1	189	40	1	0	0	0	0	0	686	989
2Q 2010	47	12	2	241	39	0	0	0	0	0	0	731	1,072
3Q 2010	39	16	0	382	49	0	0	0	0	0	0	769	1,255
4Q 2010	40	7	1	303	52	0	0	0	0	0	0	592	995
1Q 2011	47	7	0	250	42	0	0	0	0	0	0	679	1,025
2Q 2011	46	10	1	252	30	0	0	0	0	0	0	741	1,080
		1,065	56	5,515	2,173	1	-	-	10	-	-	12,291	24,847

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**TABLE 9 - MEDICAL ACTUAL DOLLARS PAID BY QUARTER**

Paid Qtr	RECA	BD	CS	CN-SEC	CN Non SEC	BS	OL	RN	Other	99	Blank	Part E	Total
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)
3Q 2001	\$ 800	-	-	-	-	-	-	-	-	-	-	-	-
4Q 2001	-	-	-	1,354	-	-	-	-	-	-	-	-	2,153
1Q 2002	82,905	1,845	225	217,818	-	-	-	-	-	-	-	-	302,794
2Q 2002	86,451	28,291	4,845	1,417,413	-	-	-	-	-	-	-	-	1,537,000
3Q 2002	186,833	127,234	4,456	1,654,488	1,371	6,072	-	-	-	-	-	-	1,980,454
4Q 2002	202,580	216,038	10,344	1,297,136	3,694	13,258	-	-	-	-	-	-	1,743,499
1Q 2003	392,775	831,366	5,530	2,076,125	28,057	98,516	-	-	-	-	-	-	3,437,246
2Q 2003	734,041	963,466	18,889	2,420,146	25,305	168,709	1,875	-	540	750	-	-	4,334,275
3Q 2003	1,091,672	1,649,495	16,497	3,178,753	33,726	150,362	-	-	1,763	-	-	-	5,223,288
4Q 2003	949,669	419,727	38,720	2,608,193	44,421	115,417	-	-	-	-	-	-	4,178,941
1Q 2004	1,259,991	924,018	27,937	4,594,394	166,743	194,426	-	-	1,000	-	-	-	7,171,777
2Q 2004	1,260,621	745,301	42,685	4,100,574	124,568	163,301	-	-	234	600	-	-	6,443,989
3Q 2004	1,250,904	561,334	21,493	3,076,747	191,368	99,185	-	-	475	-	-	-	5,207,840
4Q 2004	2,833,199	638,539	29,762	3,001,144	251,286	73,956	-	-	500	200	-	-	6,833,070
1Q 2005	3,924,156	483,679	42,801	3,136,840	266,503	68,910	-	-	1,420	-	-	-	7,931,955
2Q 2005	4,216,388	836,835	28,351	3,434,435	396,166	99,797	-	-	-	-	-	-	9,065,376
3Q 2005	3,699,132	947,371	44,822	3,500,014	540,462	104,398	-	-	732	-	-	-	110,508
4Q 2005	2,426,083	770,229	59,480	3,772,931	556,842	107,733	938	-	441	-	-	-	8,947,440
1Q 2006	5,142,580	706,722	68,704	4,091,277	583,048	64,009	146	-	720	250	-	-	11,329,909
2Q 2006	5,003,840	752,962	99,266	4,161,217	1,497,139	86,305	7,575	-	8,643	8,100	-	-	12,171,643
3Q 2006	3,704,340	922,918	66,662	3,828,325	1,025,957	102,900	16,050	4,050	30,244	26,505	-	-	10,275,911
4Q 2006	3,076,681	748,675	57,526	3,694,115	960,397	100,436	29,125	600	29,283	17,538	-	-	9,403,769
1Q 2007	4,567,892	868,780	63,602	5,181,311	1,579,038	57,595	21,000	2,400	22,405	12,026	-	-	13,410,427
2Q 2007	6,701,798	898,473	67,472	6,525,123	1,674,664	89,072	16,050	3,675	10,246	7,755	-	-	17,336,369
3Q 2007	6,658,525	1,033,543	87,650	8,583,775	2,228,949	159,891	15,318	1,950	22,015	7,902	-	-	20,343,514
4Q 2007	5,675,959	1,178,963	96,534	7,121,325	1,359,998	129,969	14,564	-	9,314	14,138	-	-	16,842,607
1Q 2008	5,858,562	1,312,483	94,699	7,014,517	1,725,985	172,203	6,246	-	3,958	5,106	-	-	17,806,320
2Q 2008	6,542,731	1,307,780	77,761	7,773,347	1,887,968	86,200	13,483	1,800	9,126	9,489	-	-	19,529,136
3Q 2008	8,788,225	991,873	73,154	10,569,627	2,775,374	183,860	17,239	-	24,904	10,252	-	-	23,312,642
4Q 2008	8,130,603	1,712,523	65,703	9,058,690	2,853,257	138,704	9,963	1,800	24,034	3,448	-	-	26,898,951
1Q 2009	8,697,989	1,489,784	35,408	11,258,232	3,438,904	150,706	13,333	2,025	48,704	4,857	-	-	30,765,001
2Q 2009	12,118,512	1,818,342	44,881	12,624,873	3,293,384	262,789	12,148	825	12,577	6,086	-	-	36,680,190
3Q 2009	16,672,558	1,785,707	35,163	14,619,912	3,984,272	199,723	13,037	2,775	33,515	15,997	-	-	46,470,051
4Q 2009	14,908,943	1,612,802	41,591	15,984,193	3,661,849	165,826	20,715	-	11,946	2,985	-	-	45,662,598
1Q 2010	18,013,046	2,739,763	56,603	16,700,066	4,160,783	200,710	23,930	-	15,370	3,300	-	-	53,421,384
2Q 2010	26,282,566	2,859,444	36,896	20,756,291	5,316,494	383,427	24,798	-	13,823	34,282	-	-	72,213,817
3Q 2010	28,383,718	2,376,477	45,674	20,204,960	5,112,599	268,932	18,087	6,450	17,199	16,612	-	-	70,419,177
4Q 2010	37,315,659	2,362,975	60,659	20,981,056	6,460,460	157,526	19,534	-	15,261	7,884	-	-	81,868,944
1Q 2011	36,133,650	2,625,446	61,648	23,429,095	5,504,432	160,585	17,890	675	23,407	450	-	-	85,548,024
2Q 2011	\$ 299,748,111	\$ 42,500,202	\$ 1,824,581	\$ 286,268,918	\$ 66,656,165	\$ 4,929,818	\$ 351,622	\$ 29,475	\$ 404,824	\$ 233,677	\$ -	\$ 127,168,688	\$ 830,116,081

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**TABLE 10 - NUMBER OF CASES MEDICAL BY QUARTER**

Paid Qtr (1)	RECA (2)	BD (3)	CS (4)	CN-SFC (5)	CN Non SEC (6)	BS (7)	OL (8)	RN (9)	Other (10)	99 (11)	Blank (12)	Part E (13)	Total (14)
3Q 2001	-	-	-	-	-	-	-	-	-	-	-	-	-
4Q 2001	3	-	-	5	-	-	-	-	-	-	-	-	8
1Q 2002	24	5	1	37	-	-	-	-	-	-	-	-	67
2Q 2002	43	21	2	82	-	-	-	-	-	-	-	-	148
3Q 2002	59	71	3	155	-	-	-	-	-	-	-	-	301
4Q 2002	71	69	4	201	7	6	-	-	-	-	-	-	366
1Q 2003	125	163	3	325	22	31	-	-	-	-	-	1	679
2Q 2003	173	212	6	396	22	47	2	-	2	-	-	7	862
3Q 2003	221	231	9	455	25	57	-	-	2	-	-	5	1,005
4Q 2003	270	243	10	447	21	60	-	-	2	-	-	4	1,055
1Q 2004	287	303	8	546	55	67	-	-	2	-	-	6	1,274
2Q 2004	300	321	7	580	73	73	-	1	2	-	-	11	1,368
3Q 2004	324	348	7	587	90	64	-	-	3	-	-	20	1,443
4Q 2004	393	329	11	578	87	51	-	-	3	1	-	8	1,461
1Q 2005	433	362	10	647	113	56	-	-	3	-	-	15	1,639
2Q 2005	528	396	10	708	129	78	-	-	-	-	-	31	1,880
3Q 2005	561	412	17	724	163	87	-	-	2	-	-	74	2,040
4Q 2005	630	396	16	775	180	81	1	-	2	-	-	77	2,158
1Q 2006	656	391	17	827	207	57	1	-	2	-	-	106	2,264
2Q 2006	712	481	23	1,051	386	74	9	-	11	1	-	262	3,019
3Q 2006	724	448	20	1,133	567	82	23	6	38	10	-	398	3,470
4Q 2006	769	437	22	1,108	532	76	32	1	35	21	-	446	3,479
1Q 2007	802	433	23	1,183	540	67	23	2	25	14	-	511	3,623
2Q 2007	999	462	24	1,374	587	85	17	2	15	4	-	742	4,311
3Q 2007	1,292	500	27	1,591	698	101	18	2	11	8	-	1,013	5,261
4Q 2007	1,166	482	27	1,412	609	96	10	-	10	7	-	843	4,662
1Q 2008	1,142	466	28	1,427	591	123	8	-	4	3	-	884	4,676
2Q 2008	1,210	448	28	1,534	703	85	12	2	11	2	-	1,043	5,078
3Q 2008	1,302	494	25	1,584	741	108	21	1	14	6	-	1,189	5,485
4Q 2008	1,394	508	29	1,784	799	117	13	-	14	6	-	1,367	6,031
1Q 2009	1,285	481	27	1,710	728	102	7	1	8	3	-	1,387	5,739
2Q 2009	1,405	509	25	1,930	820	112	9	3	10	5	-	1,606	6,434
3Q 2009	1,352	490	21	1,967	825	112	10	1	12	5	-	1,698	6,493
4Q 2009	1,409	509	20	2,083	834	132	10	2	11	6	-	1,900	6,916
1Q 2010	1,372	483	21	1,915	742	114	16	-	9	2	-	1,802	6,476
2Q 2010	1,513	518	27	2,107	802	111	14	-	10	3	-	1,971	7,076
3Q 2010	1,616	536	20	2,252	862	139	13	-	12	2	-	2,039	7,491
4Q 2010	1,629	538	22	2,379	844	148	11	2	18	3	-	2,010	7,604
1Q 2011	1,735	505	22	2,390	856	108	11	-	12	3	-	2,076	7,718
2Q 2011	1,855	523	23	2,464	921	107	10	1	17	1	-	2,093	8,015
	31,784	14,524	645	44,453	16,186	3,029	301	26	329	149	-	27,649	139,075

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**CALCULATION OF AVERAGE PART E BENEFIT**

**Benefits Paid to Employee**

Impairment Benefits

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than or Equal to			
-	50,000	5,326	128,322,053	24,094
50,000	100,000	2,784	204,355,814	73,404
100,000	150,000	1,812	225,826,373	124,628
150,000	200,000	1,014	179,187,725	176,714
200,000	250,000	597	135,703,613	227,309
		11,533	873,395,578	75,730

Lump sums

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than or Equal to			
-	50,000	1	50,000	50,000
50,000	100,000	1	72,500	72,500
100,000	150,000	2	257,500	128,750
150,000	200,000	-	-	-
200,000	250,000	2	412,500	206,250
		6	792,500	132,083

Wage Loss Benefits

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than or Equal to			
-	50,000	660	15,265,200	23,129
50,000	100,000	236	17,439,328	73,895
100,000	150,000	123	15,294,998	124,350
150,000	200,000	47	8,204,530	174,564
200,000	250,000	20	4,636,485	231,824
		1,086	60,840,541	56,023

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### CALCULATION OF AVERAGE PART E BENEFIT

Total Employee Benefit

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than or Equal to			
-	50,000	5,833	139,746,373	23,958
50,000	100,000	2,925	214,542,370	73,348
100,000	150,000	1,906	237,602,489	124,660
150,000	200,000	1,061	187,451,871	176,675
200,000	250,000	680	155,435,160	228,581
		12,405	934,778,263	75,355

Benefits Paid to Survivor

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than or Equal to			
-	50,000	1,360	40,245,950	29,593
50,000	100,000	1,358	92,777,151	68,319
100,000	150,000	10,086	1,277,895,008	126,700
150,000	200,000	315	55,171,019	175,146
200,000	250,000	20	4,635,000	231,750
		13,139	1,470,724,128	111,936

<u>Selection of Average Part E Benefit</u>		
Employee	60%	75,000
Survivor	70%	112,000
<b>Average</b>		<b>123,000</b>

Assumes 50% of employees that have received awards will die from covered condition and have eligible survivor to receive award:

Employee no survivor payment	30%	75,000
Employee with survivor payme	30%	187,000
Survivor Only	40%	112,000

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR RECA CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (b)	Estimated Ultimate Compensation (c)	Approved Cases By Filed Year (d)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		139	50,000	\$ 6,950,000	139
4	2001	1	746	50,000	37,300,000	
1	2002	2	391	50,000	19,550,000	
2	2002	3	316	50,000	15,800,000	
3	2002	4	275	50,000	13,750,000	1,728
4	2002	5	319	50,000	15,950,000	
1	2003	6	195	50,000	9,750,000	
2	2003	7	105	50,000	5,250,000	
3	2003	8	116	50,000	5,800,000	735
4	2003	9	130	50,000	6,500,000	
1	2004	10	143	50,000	7,150,000	
2	2004	11	169	50,000	8,450,000	
3	2004	12	142	50,000	7,100,000	584
4	2004	13	95	50,000	4,750,000	
1	2005	14	196	50,000	9,800,000	
2	2005	15	171	50,000	8,550,000	
3	2005	16	133	50,000	6,650,000	595
4	2005	17	118	100,000	11,800,000	
1	2006	18	111	100,000	11,100,000	
2	2006	19	100	100,000	10,000,000	
3	2006	20	141	150,000	21,150,000	470
4	2006	21	169	150,000	25,350,000	
1	2007	22	245	150,000	36,750,000	
2	2007	23	315	150,000	47,250,000	
3	2007	24	378	150,000	56,700,000	1,107
4	2007	25	221	150,000	33,150,000	
1	2008	26	172	150,000	25,800,000	
2	2008	27	106	150,000	15,900,000	
3	2008	28	158	150,000	23,700,000	657
4	2008	29	145	150,000	21,750,000	
1	2009	30	130	150,000	19,500,000	
2	2009	31	91	150,000	13,650,000	
3	2009	32	96	150,000	14,400,000	462
4	2009	33	85	150,000	12,750,000	
1	2010	34	84	150,000	12,600,000	
2	2010	35	86	150,000	12,900,000	
3	2010	36	80	150,000	12,000,000	335



## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR RECA CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (b)	Estimated Ultimate Compensation (c)	Approved Cases By Filed Year (d)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
4	2010	37	70	150,000	10,500,000	
1	2011	38	73	150,000	10,950,000	
2	2011	39	84	150,000	12,600,000	
3	2011	40	80	150,000	12,000,000	307
4	2011	41	77	150,000	11,550,000	
1	2012	42	74	150,000	11,100,000	
2	2012	43	71	150,000	10,650,000	
3	2012	44	69	150,000	10,350,000	291
4	2012	45	67	150,000	10,050,000	
1	2013	46	64	150,000	9,600,000	
2	2013	47	62	150,000	9,300,000	
3	2013	48	60	150,000	9,000,000	253
4	2013	49	58	150,000	8,700,000	
1	2014	50	57	150,000	8,550,000	
2	2014	51	55	150,000	8,250,000	
3	2014	52	53	150,000	7,950,000	223
4	2014	53	52	150,000	7,800,000	
1	2015	54	50	150,000	7,500,000	
2	2015	55	49	150,000	7,350,000	
3	2015	56	48	150,000	7,200,000	199
4	2015	57	46	150,000	6,900,000	
1	2016	58	45	150,000	6,750,000	
2	2016	59	44	150,000	6,600,000	
3	2016	60	43	150,000	6,450,000	178
4	2016	61	42	150,000	6,300,000	
1	2017	62	40	150,000	6,000,000	
2	2017	63	39	150,000	5,850,000	
3	2017	64	38	150,000	5,700,000	159
4	2017	65	37	150,000	5,550,000	
1	2018	66	37	150,000	5,550,000	
2	2018	67	36	150,000	5,400,000	
3	2018	68	35	150,000	5,250,000	145
4	2018	69	34	150,000	5,100,000	
1	2019	70	33	150,000	4,950,000	
2	2019	71	32	150,000	4,800,000	
3	2019	72	31	150,000	4,650,000	130
4	2019	73	30	150,000	4,500,000	

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR RECA CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (b)	Estimated Ultimate Compensation (c)	Approved Cases By Filed Year (d)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	2020	74	30	150,000	4,500,000	
2	2020	75	29	150,000	4,350,000	
3	2020	76	28	150,000	4,200,000	117
4	2020	77	27	150,000	4,050,000	
1	2021	78	27	150,000	4,050,000	
2	2021	79	26	150,000	3,900,000	
3	2021	80	25	150,000	3,750,000	105
4	2021	81	24	150,000	3,600,000	
1	2022	82	24	150,000	3,600,000	
2	2022	83	23	150,000	3,450,000	
3	2022	84	22	150,000	3,300,000	93
4	2022	85	22	150,000	3,300,000	
1	2023	86	21	150,000	3,150,000	
2	2023	87	20	150,000	3,000,000	
3	2023	88	20	150,000	3,000,000	83
4	2023	89	19	150,000	2,850,000	
1	2024	90	18	150,000	2,700,000	
2	2024	91	18	150,000	2,700,000	
3	2024	92	17	150,000	2,550,000	72
4	2024	93	16	150,000	2,400,000	
1	2025	94	16	150,000	2,400,000	
2	2025	95	15	150,000	2,250,000	
3	2025	96	14	150,000	2,100,000	61
4	2025	97	14	150,000	2,100,000	
1	2026	98	13	150,000	1,950,000	
2	2026	99	12	150,000	1,800,000	
3	2026	100	12	150,000	1,800,000	51
4	2026	101	11	150,000	1,650,000	
1	2027	102	11	150,000	1,650,000	
2	2027	103	10	150,000	1,500,000	
3	2027	104	9	150,000	1,350,000	41
4	2027	105	9	150,000	1,350,000	
1	2028	106	8	150,000	1,200,000	
2	2028	107	7	150,000	1,050,000	
3	2028	108	7	150,000	1,050,000	31
4	2028	109	6	150,000	900,000	
1	2029	110	6	150,000	900,000	
2	2029	111	5	150,000	750,000	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR RECA CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (b)	Estimated Ultimate Compensation (c)	Approved Cases By Filed Year (d)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2029	112	4	150,000	600,000	21
4	2029	113	4	150,000	600,000	
1	2030	114	3	150,000	450,000	
2	2030	115	2	150,000	300,000	
3	2030	116	2	150,000	300,000	11
4	2030	117	1	150,000	150,000	
1	2031	118	1	150,000	150,000	
2	2031	119	-	150,000	-	
3	2031	120	-	150,000	-	2
					\$ 1,013,200,000	9,385

Notes: (a) Actual cases from Exhibit 3, Table 5, Column (2). Projected cases based on judgment.  
 (b) [ (4) × (5) ]  
 (c) Based on actual benefits from EEOCIPA.  
 (d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR BERYLLIUM DISEASE CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		2	150,000	\$ 300,000	2
4	2001	1	28	150,000	4,200,000	
1	2002	2	93	150,000	13,950,000	
2	2002	3	172	150,000	25,800,000	
3	2002	4	119	150,000	17,850,000	412
4	2002	5	110	150,000	16,500,000	
1	2003	6	112	150,000	16,800,000	
2	2003	7	80	150,000	12,000,000	
3	2003	8	64	150,000	9,600,000	366
4	2003	9	68	150,000	10,200,000	
1	2004	10	82	150,000	12,300,000	
2	2004	11	55	150,000	8,250,000	
3	2004	12	63	150,000	9,450,000	268
4	2004	13	49	150,000	7,350,000	
1	2005	14	53	150,000	7,950,000	
2	2005	15	47	150,000	7,050,000	
3	2005	16	34	150,000	5,100,000	183
4	2005	17	39	150,000	5,850,000	
1	2006	18	38	150,000	5,700,000	
2	2006	19	45	150,000	6,750,000	
3	2006	20	42	150,000	6,300,000	164
4	2006	21	35	150,000	5,250,000	
1	2007	22	46	150,000	6,900,000	
2	2007	23	28	150,000	4,200,000	
3	2007	24	35	150,000	5,250,000	144
4	2007	25	24	150,000	3,600,000	
1	2008	26	24	150,000	3,600,000	
2	2008	27	33	150,000	4,950,000	
3	2008	28	32	150,000	4,800,000	113
4	2008	29	33	150,000	4,950,000	
1	2009	30	32	150,000	4,800,000	
2	2009	31	23	150,000	3,450,000	
3	2009	32	22	150,000	3,300,000	110
4	2009	33	22	150,000	3,300,000	
1	2010	34	20	150,000	3,000,000	
2	2010	35	21	150,000	3,150,000	

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR BERYLLIUM DISEASE CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
3	2010	36	21	150,000	3,150,000	84	
4	2010	37	10	150,000	1,500,000		
1	2011	38	7	150,000	1,050,000	50	
2	2011	39	Actual ↑ 11	150,000	1,650,000		
3	2011	40	Projected ↓ 22	150,000	3,300,000		
4	2011	41	21	150,000	3,150,000		
1	2012	42	20	150,000	3,000,000		
2	2012	43	20	150,000	3,000,000		
3	2012	44	19	150,000	2,850,000		80
4	2012	45	19	150,000	2,850,000		
1	2013	46	18	150,000	2,700,000		72
2	2013	47	18	150,000	2,700,000		
3	2013	48	17	150,000	2,550,000		
4	2013	49	17	150,000	2,550,000		
1	2014	50	16	150,000	2,400,000	65	
2	2014	51	16	150,000	2,400,000		
3	2014	52	16	150,000	2,400,000		
4	2014	53	15	150,000	2,250,000		
1	2015	54	15	150,000	2,250,000	59	
2	2015	55	15	150,000	2,250,000		
3	2015	56	14	150,000	2,100,000		
4	2015	57	14	150,000	2,100,000		
1	2016	58	14	150,000	2,100,000	54	
2	2016	59	13	150,000	1,950,000		
3	2016	60	13	150,000	1,950,000		
4	2016	61	13	150,000	1,950,000		
1	2017	62	12	150,000	1,800,000	49	
2	2017	63	12	150,000	1,800,000		
3	2017	64	12	150,000	1,800,000		
4	2017	65	11	150,000	1,650,000		
1	2018	66	11	150,000	1,650,000	44	
2	2018	67	11	150,000	1,650,000		
3	2018	68	11	150,000	1,650,000		
4	2018	69	10	150,000	1,500,000		
1	2019	70	10	150,000	1,500,000		
2	2019	71	10	150,000	1,500,000		

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR BERYLLIUM DISEASE CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2019	72	10	150,000	1,500,000	40
4	2019	73	9	150,000	1,350,000	
1	2020	74	9	150,000	1,350,000	
2	2020	75	9	150,000	1,350,000	
3	2020	76	9	150,000	1,350,000	36
4	2020	77	8	150,000	1,200,000	
1	2021	78	8	150,000	1,200,000	
2	2021	79	8	150,000	1,200,000	
3	2021	80	8	150,000	1,200,000	32
4	2021	81	8	150,000	1,200,000	
1	2022	82	7	150,000	1,050,000	
2	2022	83	7	150,000	1,050,000	
3	2022	84	7	150,000	1,050,000	29
4	2022	85	7	150,000	1,050,000	
1	2023	86	7	150,000	1,050,000	
2	2023	87	6	150,000	900,000	
3	2023	88	6	150,000	900,000	26
4	2023	89	6	150,000	900,000	
1	2024	90	6	150,000	900,000	
2	2024	91	6	150,000	900,000	
3	2024	92	5	150,000	750,000	23
4	2024	93	5	150,000	750,000	
1	2025	94	5	150,000	750,000	
2	2025	95	5	150,000	750,000	
3	2025	96	4	150,000	600,000	19
4	2025	97	4	150,000	600,000	
1	2026	98	4	150,000	600,000	
2	2026	99	4	150,000	600,000	
3	2026	100	4	150,000	600,000	16
4	2026	101	3	150,000	450,000	
1	2027	102	3	150,000	450,000	
2	2027	103	3	150,000	450,000	
3	2027	104	3	150,000	450,000	12
4	2027	105	3	150,000	450,000	
1	2028	106	3	150,000	450,000	
2	2028	107	2	150,000	300,000	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR BERYLLIUM DISEASE CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2028	108	2	150,000	300,000	10
4	2028	109	2	150,000	300,000	
1	2029	110	2	150,000	300,000	
2	2029	111	2	150,000	300,000	
3	2029	112	1	150,000	150,000	7
4	2029	113	1	150,000	150,000	
1	2030	114	1	150,000	150,000	
2	2030	115	1	150,000	150,000	
3	2030	116	1	150,000	150,000	4
4	2030	117	-	150,000	-	
1	2031	118	-	150,000	-	
2	2031	119	-	150,000	-	
3	2031	120	-	150,000	-	-
					\$ 385,950,000	2,573

Notes: (a) Actual cases from Exhibit 3, Table 5, Column (3). Projected cases based on judgment.  
 (b) [ (4) × (5) ]  
 (c) Based on actual benefits from EEOCIPA.  
 (d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CHRONIC SILICOSIS CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		1	150,000	\$ 150,000	1
4	2001	1	6	150,000	900,000	
1	2002	2	6	150,000	900,000	
2	2002	3	4	150,000	600,000	
3	2002	4	7	150,000	1,050,000	23
4	2002	5	4	150,000	600,000	
1	2003	6	2	150,000	300,000	
2	2003	7	1	150,000	150,000	
3	2003	8	2	150,000	300,000	9
4	2003	9	2	150,000	300,000	
1	2004	10	1	150,000	150,000	
2	2004	11	2	150,000	300,000	
3	2004	12	5	150,000	750,000	10
4	2004	13	2	150,000	300,000	
1	2005	14	2	150,000	300,000	
2	2005	15	1	150,000	150,000	
3	2005	16	1	150,000	150,000	6
4	2005	17	1	150,000	150,000	
1	2006	18	1	150,000	150,000	
2	2006	19	4	150,000	600,000	
3	2006	20	1	150,000	150,000	7
4	2006	21	4	150,000	600,000	
1	2007	22	1	150,000	150,000	
2	2007	23	2	150,000	300,000	
3	2007	24	1	150,000	150,000	8
4	2007	25	4	150,000	600,000	
1	2008	26	2	150,000	300,000	
2	2008	27	2	150,000	300,000	
3	2008	28	3	150,000	450,000	11
4	2008	29	2	150,000	300,000	
1	2009	30	1	150,000	150,000	
2	2009	31	1	150,000	150,000	
3	2009	32	1	150,000	150,000	5
4	2009	33	1	150,000	150,000	
1	2010	34	2	150,000	300,000	
2	2010	35	2	150,000	300,000	



## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR CHRONIC SILICOSIS CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
3	2010	36	-	150,000	-	5	
4	2010	37	-	150,000	-		
1	2011	38	-	150,000	-		
2	2011	39	<b>Actual ↑</b>	150,000	-		
3	2011	40	<b>Projected ↓</b>	2	150,000	300,000	2
4	2011	41		2	150,000	300,000	
1	2012	42		2	150,000	300,000	
2	2012	43		2	150,000	300,000	
3	2012	44		2	150,000	300,000	8
4	2012	45		2	150,000	300,000	
1	2013	46		2	150,000	300,000	
2	2013	47		2	150,000	300,000	
3	2013	48		2	150,000	300,000	8
4	2013	49		2	150,000	300,000	
1	2014	50		2	150,000	300,000	
2	2014	51		2	150,000	300,000	
3	2014	52		2	150,000	300,000	8
4	2014	53		2	150,000	300,000	
1	2015	54		2	150,000	300,000	
2	2015	55		2	150,000	300,000	
3	2015	56		2	150,000	300,000	8
4	2015	57		2	150,000	300,000	
1	2016	58		1	150,000	150,000	
2	2016	59		1	150,000	150,000	
3	2016	60		1	150,000	150,000	5
4	2016	61		1	150,000	150,000	
1	2017	62		1	150,000	150,000	
2	2017	63		1	150,000	150,000	
3	2017	64		1	150,000	150,000	4
4	2017	65		1	150,000	150,000	
1	2018	66		1	150,000	150,000	
2	2018	67		1	150,000	150,000	
3	2018	68		1	150,000	150,000	4
4	2018	69		1	150,000	150,000	
1	2019	70		1	150,000	150,000	
2	2019	71		1	150,000	150,000	

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR CHRONIC SILICOSIS CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2019	72	1	150,000	150,000	4
4	2019	73	1	150,000	150,000	
1	2020	74	1	150,000	150,000	
2	2020	75	1	150,000	150,000	
3	2020	76	1	150,000	150,000	4
4	2020	77	1	150,000	150,000	
1	2021	78	1	150,000	150,000	
2	2021	79	1	150,000	150,000	
3	2021	80	1	150,000	150,000	4
4	2021	81	1	150,000	150,000	
1	2022	82	1	150,000	150,000	
2	2022	83	1	150,000	150,000	
3	2022	84	1	150,000	150,000	4
4	2022	85	1	150,000	150,000	
1	2023	86	1	150,000	150,000	
2	2023	87	1	150,000	150,000	
3	2023	88	1	150,000	150,000	4
4	2023	89	1	150,000	150,000	
1	2024	90	1	150,000	150,000	
2	2024	91	1	150,000	150,000	
3	2024	92	1	150,000	150,000	4
4	2024	93	1	150,000	150,000	
1	2025	94	1	150,000	150,000	
2	2025	95	1	150,000	150,000	
3	2025	96	1	150,000	150,000	4
4	2025	97	1	150,000	150,000	
1	2026	98	1	150,000	150,000	
2	2026	99	-	150,000	-	
3	2026	100	-	150,000	-	2
4	2026	101	-	150,000	-	
1	2027	102	-	150,000	-	
2	2027	103	-	150,000	-	
3	2027	104	-	150,000	-	-
4	2027	105	-	150,000	-	
1	2028	106	-	150,000	-	
2	2028	107	-	150,000	-	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CHRONIC SILICOSIS CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2028	108	-	150,000	-	-
4	2028	109	-	150,000	-	-
1	2029	110	-	150,000	-	-
2	2029	111	-	150,000	-	-
3	2029	112	-	150,000	-	-
4	2029	113	-	150,000	-	-
1	2030	114	-	150,000	-	-
2	2030	115	-	150,000	-	-
3	2030	116	-	150,000	-	-
4	2030	117	-	150,000	-	-
1	2031	118	-	150,000	-	-
2	2031	119	-	150,000	-	-
3	2031	120	-	150,000	-	-
					\$ 24,300,000	162

Notes: (a) Actual cases from Exhibit 3, Table 5, Column (4). Projected cases based on judgment.

(b) [ (4) × (5) ]

(c) Based on actual benefits from EEOICPA.

(d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CANCER SEC CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		37	150,000	\$ 5,550,000	37
4	2001	1	160	150,000	24,000,000	
1	2002	2	417	150,000	62,550,000	
2	2002	3	323	150,000	48,450,000	
3	2002	4	422	150,000	63,300,000	1,322
4	2002	5	325	150,000	48,750,000	
1	2003	6	408	150,000	61,200,000	
2	2003	7	311	150,000	46,650,000	
3	2003	8	177	150,000	26,550,000	1,221
4	2003	9	178	150,000	26,700,000	
1	2004	10	158	150,000	23,700,000	
2	2004	11	167	150,000	25,050,000	
3	2004	12	184	150,000	27,600,000	687
4	2004	13	176	150,000	26,400,000	
1	2005	14	164	150,000	24,600,000	
2	2005	15	177	150,000	26,550,000	
3	2005	16	359	150,000	53,850,000	876
4	2005	17	306	150,000	45,900,000	
1	2006	18	377	150,000	56,550,000	
2	2006	19	385	150,000	57,750,000	
3	2006	20	338	150,000	50,700,000	1,406
4	2006	21	395	150,000	59,250,000	
1	2007	22	337	150,000	50,550,000	
2	2007	23	494	150,000	74,100,000	
3	2007	24	437	150,000	65,550,000	1,663
4	2007	25	613	150,000	91,950,000	
1	2008	26	524	150,000	78,600,000	
2	2008	27	583	150,000	87,450,000	
3	2008	28	674	150,000	101,100,000	2,394
4	2008	29	836	150,000	125,400,000	
1	2009	30	471	150,000	70,650,000	
2	2009	31	476	150,000	71,400,000	
3	2009	32	382	150,000	57,300,000	2,165
4	2009	33	341	150,000	51,150,000	
1	2010	34	593	150,000	88,950,000	
2	2010	35	736	150,000	110,400,000	

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR CANCER SEC CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2010	36	1,138	150,000	170,700,000	2,808
4	2010	37	1,188	150,000	178,200,000	
1	2011	38	822	150,000	123,300,000	
2	2011	39	Actual ↑ 788	150,000	118,200,000	
3	2011	40	Projected ↓ 972	150,000	145,755,000	3,770
4	2011	41	959	150,000	143,910,000	
1	2012	42	947	150,000	142,065,000	
2	2012	43	935	150,000	140,220,000	
3	2012	44	923	150,000	138,375,000	3,764
4	2012	45	910	150,000	136,530,000	
1	2013	46	898	150,000	134,685,000	
2	2013	47	886	150,000	132,840,000	
3	2013	48	873	150,000	130,995,000	3,567
4	2013	49	861	150,000	129,150,000	
1	2014	50	849	150,000	127,305,000	
2	2014	51	836	150,000	125,460,000	
3	2014	52	824	150,000	123,615,000	3,370
4	2014	53	812	150,000	121,770,000	
1	2015	54	800	150,000	119,925,000	
2	2015	55	787	150,000	118,080,000	
3	2015	56	775	150,000	116,235,000	3,173
4	2015	57	763	150,000	114,390,000	
1	2016	58	750	150,000	112,545,000	
2	2016	59	738	150,000	110,700,000	
3	2016	60	726	150,000	108,855,000	2,977
4	2016	61	713	150,000	107,010,000	
1	2017	62	701	150,000	105,165,000	
2	2017	63	689	150,000	103,320,000	
3	2017	64	677	150,000	101,475,000	2,780
4	2017	65	664	150,000	99,630,000	
1	2018	66	652	150,000	97,785,000	
2	2018	67	640	150,000	95,940,000	
3	2018	68	627	150,000	94,095,000	2,583
4	2018	69	615	150,000	92,250,000	
1	2019	70	603	150,000	90,405,000	
2	2019	71	590	150,000	88,560,000	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CANCER SEC CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2019	72	578	150,000	86,715,000	2,386
4	2019	73	566	150,000	84,870,000	
1	2020	74	554	150,000	83,025,000	
2	2020	75	541	150,000	81,180,000	
3	2020	76	529	150,000	79,335,000	2,189
4	2020	77	517	150,000	77,490,000	
1	2021	78	504	150,000	75,645,000	
2	2021	79	492	150,000	73,800,000	
3	2021	80	480	150,000	71,955,000	1,993
4	2021	81	467	150,000	70,110,000	
1	2022	82	455	150,000	68,265,000	
2	2022	83	443	150,000	66,420,000	
3	2022	84	431	150,000	64,575,000	1,796
4	2022	85	418	150,000	62,730,000	
1	2023	86	406	150,000	60,885,000	
2	2023	87	394	150,000	59,040,000	
3	2023	88	381	150,000	57,195,000	1,599
4	2023	89	369	150,000	55,350,000	
1	2024	90	357	150,000	53,505,000	
2	2024	91	344	150,000	51,660,000	
3	2024	92	332	150,000	49,815,000	1,402
4	2024	93	320	150,000	47,970,000	
1	2025	94	308	150,000	46,125,000	
2	2025	95	295	150,000	44,280,000	
3	2025	96	283	150,000	42,435,000	1,205
4	2025	97	271	150,000	40,590,000	
1	2026	98	258	150,000	38,745,000	
2	2026	99	246	150,000	36,900,000	
3	2026	100	234	150,000	35,055,000	1,009
4	2026	101	221	150,000	33,210,000	
1	2027	102	209	150,000	31,365,000	
2	2027	103	197	150,000	29,520,000	
3	2027	104	185	150,000	27,675,000	812
4	2027	105	172	150,000	25,830,000	
1	2028	106	160	150,000	23,985,000	
2	2028	107	148	150,000	22,140,000	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CANCER SEC CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2028	108	135	150,000	20,295,000	615
4	2028	109	123	150,000	18,450,000	
1	2029	110	111	150,000	16,605,000	
2	2029	111	98	150,000	14,760,000	
3	2029	112	86	150,000	12,915,000	418
4	2029	113	74	150,000	11,070,000	
1	2030	114	62	150,000	9,225,000	
2	2030	115	49	150,000	7,380,000	
3	2030	116	37	150,000	5,535,000	221
4	2030	117	25	150,000	3,690,000	
1	2031	118	12	150,000	1,845,000	
2	2031	119	-	150,000	-	
3	2031	120	-	150,000	-	37
					\$ 8,436,750,000	56,245

Notes: (a) Actual cases from Exhibit 3, Table 5, Column (5). Projected cases based on judgment.  
 (b) [ (4) × (5) ]  
 (c) Based on actual benefits from EEOCIPA.  
 (d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CANCER NON SEC CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		-	150,000	\$ -	-
4	2001	1	-	150,000	-	
1	2002	2	3	150,000	450,000	
2	2002	3	7	150,000	1,050,000	
3	2002	4	11	150,000	1,650,000	21
4	2002	5	14	150,000	2,100,000	
1	2003	6	14	150,000	2,100,000	
2	2003	7	43	150,000	6,450,000	
3	2003	8	97	150,000	14,550,000	168
4	2003	9	137	150,000	20,550,000	
1	2004	10	108	150,000	16,200,000	
2	2004	11	117	150,000	17,550,000	
3	2004	12	122	150,000	18,300,000	484
4	2004	13	165	150,000	24,750,000	
1	2005	14	159	150,000	23,850,000	
2	2005	15	233	150,000	34,950,000	
3	2005	16	313	150,000	46,950,000	870
4	2005	17	237	150,000	35,550,000	
1	2006	18	295	150,000	44,250,000	
2	2006	19	339	150,000	50,850,000	
3	2006	20	357	150,000	53,550,000	1,228
4	2006	21	290	150,000	43,500,000	
1	2007	22	258	150,000	38,700,000	
2	2007	23	284	150,000	42,600,000	
3	2007	24	152	150,000	22,800,000	984
4	2007	25	151	150,000	22,650,000	
1	2008	26	152	150,000	22,800,000	
2	2008	27	193	150,000	28,950,000	
3	2008	28	201	150,000	30,150,000	697
4	2008	29	139	150,000	20,850,000	
1	2009	30	120	150,000	18,000,000	
2	2009	31	121	150,000	18,150,000	
3	2009	32	119	150,000	17,850,000	499
4	2009	33	98	150,000	14,700,000	
1	2010	34	88	150,000	13,200,000	
2	2010	35	82	150,000	12,300,000	



## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR CANCER NON SEC CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2010	36	105	150,000	15,750,000	373
4	2010	37	83	150,000	12,450,000	
1	2011	38	70	150,000	10,500,000	
2	2011	39	78	150,000	11,700,000	
3	2011	40	83	150,000	12,493,367	314
4	2011	41	80	150,000	12,043,703	
1	2012	42	77	150,000	11,618,283	
2	2012	43	75	150,000	11,215,489	
3	2012	44	72	150,000	10,833,811	305
4	2012	45	70	150,000	10,471,835	
1	2013	46	68	150,000	10,128,243	
2	2013	47	65	150,000	9,801,801	
3	2013	48	63	150,000	9,491,359	266
4	2013	49	61	150,000	9,195,841	
1	2014	50	59	150,000	8,914,243	
2	2014	51	58	150,000	8,645,626	
3	2014	52	56	150,000	8,389,115	234
4	2014	53	54	150,000	8,143,892	
1	2015	54	53	150,000	7,909,193	
2	2015	55	51	150,000	7,684,306	
3	2015	56	50	150,000	7,468,563	208
4	2015	57	48	150,000	7,261,345	
1	2016	58	47	150,000	7,062,070	
2	2016	59	46	150,000	6,870,198	
3	2016	60	45	150,000	6,685,223	186
4	2016	61	43	150,000	6,506,674	
1	2017	62	42	150,000	6,334,111	
2	2017	63	41	150,000	6,167,123	
3	2017	64	40	150,000	6,005,327	167
4	2017	65	39	150,000	5,848,366	
1	2018	66	38	150,000	5,695,907	
2	2018	67	37	150,000	5,547,639	
3	2018	68	36	150,000	5,403,271	150
4	2018	69	35	150,000	5,262,534	
1	2019	70	34	150,000	5,125,175	
2	2019	71	33	150,000	4,990,960	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CANCER NON SEC CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2019	72	32	150,000	4,859,669	135
4	2019	73	32	150,000	4,731,098	
1	2020	74	31	150,000	4,605,056	
2	2020	75	30	150,000	4,481,367	
3	2020	76	29	150,000	4,359,864	121
4	2020	77	28	150,000	4,240,394	
1	2021	78	27	150,000	4,122,813	
2	2021	79	27	150,000	4,006,988	
3	2021	80	26	150,000	3,892,793	108
4	2021	81	25	150,000	3,780,114	
1	2022	82	24	150,000	3,668,841	
2	2022	83	24	150,000	3,558,875	
3	2022	84	23	150,000	3,450,122	96
4	2022	85	22	150,000	3,342,494	
1	2023	86	22	150,000	3,235,911	
2	2023	87	21	150,000	3,130,297	
3	2023	88	20	150,000	3,025,582	85
4	2023	89	19	150,000	2,921,700	
1	2024	90	19	150,000	2,818,591	
2	2024	91	18	150,000	2,716,198	
3	2024	92	17	150,000	2,614,469	74
4	2024	93	17	150,000	2,513,354	
1	2025	94	16	150,000	2,412,809	
2	2025	95	15	150,000	2,312,791	
3	2025	96	15	150,000	2,213,261	63
4	2025	97	14	150,000	2,114,182	
1	2026	98	13	150,000	2,015,521	
2	2026	99	13	150,000	1,917,246	
3	2026	100	12	150,000	1,819,329	52
4	2026	101	11	150,000	1,721,740	
1	2027	102	11	150,000	1,624,457	
2	2027	103	10	150,000	1,527,455	
3	2027	104	10	150,000	1,430,713	42
4	2027	105	9	150,000	1,334,210	
1	2028	106	8	150,000	1,237,928	
2	2028	107	8	150,000	1,141,850	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR CANCER NON SEC CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2028	108	7	150,000	1,045,960	32
4	2028	109	6	150,000	950,242	
1	2029	110	6	150,000	854,684	
2	2029	111	5	150,000	759,272	
3	2029	112	4	150,000	663,994	22
4	2029	113	4	150,000	568,841	
1	2030	114	3	150,000	473,800	
2	2030	115	3	150,000	378,865	
3	2030	116	2	150,000	284,024	11
4	2030	117	1	150,000	189,272	
1	2031	118	1	150,000	94,599	
2	2031	119	-	150,000	-	
3	2031	120	-	150,000	-	2
					\$ 1,199,628,233	7,998

Notes: (a) Actual cases from Exhibit 3, Table 5, Column (6). Projected cases based on judgment.  
 (b) [ (4) × (5) ]  
 (c) Based on actual benefits from EEOCIPA.  
 (d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR BERYLLIUM SENSITIVITY CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		-	-	\$ -	-
4	2001	1	-	-	-	-
1	2002	2	8	-	-	-
2	2002	3	35	-	-	-
3	2002	4	71	-	-	114
4	2002	5	141	-	-	-
1	2003	6	116	-	-	-
2	2003	7	48	-	-	-
3	2003	8	42	-	-	347
4	2003	9	25	-	-	-
1	2004	10	29	-	-	-
2	2004	11	26	-	-	-
3	2004	12	20	-	-	100
4	2004	13	17	-	-	-
1	2005	14	8	-	-	-
2	2005	15	17	-	-	-
3	2005	16	12	-	-	54
4	2005	17	12	-	-	-
1	2006	18	12	-	-	-
2	2006	19	10	-	-	-
3	2006	20	9	-	-	43
4	2006	21	18	-	-	-
1	2007	22	23	-	-	-
2	2007	23	32	-	-	-
3	2007	24	32	-	-	105
4	2007	25	34	-	-	-
1	2008	26	31	-	-	-
2	2008	27	20	-	-	-
3	2008	28	13	-	-	98
4	2008	29	25	-	-	-
1	2009	30	9	-	-	-
2	2009	31	16	-	-	-
3	2009	32	15	-	-	65
4	2009	33	16	-	-	-
1	2010	34	16	-	-	-
2	2010	35	12	-	-	-

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR BERYLLIUM SENSITIVITY CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2010	36	8	-	-	52
4	2010	37	14	-	-	
1	2011	38	18	-	-	
2	2011	39	14	-	-	
3	2011	40	16	-	-	62
4	2011	41	18	-	-	
1	2012	42	16	-	-	
2	2012	43	16	-	-	
3	2012	44	16	-	-	66
4	2012	45	15	-	-	
1	2013	46	15	-	-	
2	2013	47	15	-	-	
3	2013	48	15	-	-	60
4	2013	49	15	-	-	
1	2014	50	14	-	-	
2	2014	51	14	-	-	
3	2014	52	14	-	-	57
4	2014	53	14	-	-	
1	2015	54	14	-	-	
2	2015	55	13	-	-	
3	2015	56	13	-	-	54
4	2015	57	13	-	-	
1	2016	58	13	-	-	
2	2016	59	13	-	-	
3	2016	60	12	-	-	51
4	2016	61	12	-	-	
1	2017	62	12	-	-	
2	2017	63	12	-	-	
3	2017	64	12	-	-	48
4	2017	65	11	-	-	
1	2018	66	11	-	-	
2	2018	67	11	-	-	
3	2018	68	11	-	-	44
4	2018	69	11	-	-	
1	2019	70	10	-	-	
2	2019	71	10	-	-	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR BERYLLIUM SENSITIVITY CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2019	72	10	-	-	41
4	2019	73	10	-	-	
1	2020	74	10	-	-	
2	2020	75	9	-	-	
3	2020	76	9	-	-	38
4	2020	77	9	-	-	
1	2021	78	9	-	-	
2	2021	79	9	-	-	
3	2021	80	8	-	-	34
4	2021	81	8	-	-	
1	2022	82	8	-	-	
2	2022	83	8	-	-	
3	2022	84	7	-	-	31
4	2022	85	7	-	-	
1	2023	86	7	-	-	
2	2023	87	7	-	-	
3	2023	88	7	-	-	28
4	2023	89	6	-	-	
1	2024	90	6	-	-	
2	2024	91	6	-	-	
3	2024	92	6	-	-	24
4	2024	93	6	-	-	
1	2025	94	5	-	-	
2	2025	95	5	-	-	
3	2025	96	5	-	-	21
4	2025	97	5	-	-	
1	2026	98	5	-	-	
2	2026	99	4	-	-	
3	2026	100	4	-	-	18
4	2026	101	4	-	-	
1	2027	102	4	-	-	
2	2027	103	3	-	-	
3	2027	104	3	-	-	14
4	2027	105	3	-	-	
1	2028	106	3	-	-	
2	2028	107	3	-	-	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR BERYLLIUM SENSITIVITY CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2028	108	2	-	-	11
4	2028	109	2	-	-	
1	2029	110	2	-	-	
2	2029	111	2	-	-	
3	2029	112	2	-	-	7
4	2029	113	1	-	-	
1	2030	114	1	-	-	
2	2030	115	1	-	-	
3	2030	116	1	-	-	4
4	2030	117	0	-	-	
1	2031	118	0	-	-	
2	2031	119	-	-	-	
3	2031	120	-	-	-	1
					\$ -	1,693

Notes: (a) Actual cases from Exhibit 3, Table 5, Column (7). Projected cases based on judgment.  
 (b) [ (4) × (5) ]  
 (c) Based on actual benefits from EEOCIPA.  
 (d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR PART E CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2001		-	123,000	\$ -	-
4	2001	1	-	123,000	-	-
1	2002	2	-	123,000	-	-
2	2002	3	-	123,000	-	-
3	2002	4	-	123,000	-	-
4	2002	5	-	123,000	-	-
1	2003	6	-	123,000	-	-
2	2003	7	-	123,000	-	-
3	2003	8	-	123,000	-	-
4	2003	9	-	123,000	-	-
1	2004	10	-	123,000	-	-
2	2004	11	-	123,000	-	-
3	2004	12	-	123,000	-	-
4	2004	13	2	123,000	246,000	-
1	2005	14	323	123,000	39,729,000	-
2	2005	15	383	123,000	47,109,000	-
3	2005	16	1,217	123,000	149,691,000	1,925
4	2005	17	443	123,000	54,489,000	-
1	2006	18	732	123,000	90,036,000	-
2	2006	19	1,746	123,000	214,758,000	-
3	2006	20	1,245	123,000	153,135,000	4,166
4	2006	21	992	123,000	122,016,000	-
1	2007	22	968	123,000	119,064,000	-
2	2007	23	1,308	123,000	160,884,000	-
3	2007	24	1,205	123,000	148,215,000	4,473
4	2007	25	1,075	123,000	132,225,000	-
1	2008	26	812	123,000	99,876,000	-
2	2008	27	915	123,000	112,545,000	-
3	2008	28	963	123,000	118,449,000	3,765
4	2008	29	977	123,000	120,171,000	-
1	2009	30	698	123,000	85,854,000	-
2	2009	31	690	123,000	84,870,000	-
3	2009	32	608	123,000	74,784,000	2,973
4	2009	33	538	123,000	66,174,000	-
1	2010	34	593	123,000	72,939,000	-
2	2010	35	530	123,000	65,190,000	-



## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR PART E CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2010	36	670	123,000	82,410,000	2,331
4	2010	37	514	123,000	63,222,000	
1	2011	38	364	123,000	44,772,000	
2	2011	39	<b>Actual ↑</b> 268	123,000	32,964,000	
3	2011	40	<b>Projected ↓</b> 722	123,000	88,748,973	1,868
4	2011	41	716	123,000	88,110,491	
1	2012	42	711	123,000	87,472,009	
2	2012	43	706	123,000	86,833,527	
3	2012	44	701	123,000	86,195,045	2,834
4	2012	45	696	123,000	85,556,564	
1	2013	46	690	123,000	84,918,082	
2	2013	47	685	123,000	84,279,600	
3	2013	48	680	123,000	83,641,118	2,751
4	2013	49	675	123,000	83,002,636	
1	2014	50	670	123,000	82,364,155	
2	2014	51	664	123,000	81,725,673	
3	2014	52	659	123,000	81,087,191	2,668
4	2014	53	654	123,000	80,448,709	
1	2015	54	649	123,000	79,810,227	
2	2015	55	644	123,000	79,171,745	
3	2015	56	638	123,000	78,533,264	2,585
4	2015	57	633	123,000	77,894,782	
1	2016	58	628	123,000	77,256,300	
2	2016	59	623	123,000	76,617,818	
3	2016	60	618	123,000	75,979,336	2,502
4	2016	61	613	123,000	75,340,855	
1	2017	62	607	123,000	74,702,373	
2	2017	63	602	123,000	74,063,891	
3	2017	64	597	123,000	73,425,409	2,419
4	2017	65	592	123,000	72,786,927	
1	2018	66	587	123,000	72,148,445	
2	2018	67	581	123,000	71,509,964	
3	2018	68	576	123,000	70,871,482	2,336
4	2018	69	571	123,000	70,233,000	
1	2019	70	566	123,000	69,594,518	
2	2019	71	561	123,000	68,956,036	

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR PART E CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2019	72	555	123,000	68,317,555	2,253
4	2019	73	550	123,000	67,679,073	
1	2020	74	545	123,000	67,040,591	
2	2020	75	540	123,000	66,402,109	
3	2020	76	535	123,000	65,763,627	2,170
4	2020	77	529	123,000	65,125,145	
1	2021	78	524	123,000	64,486,664	
2	2021	79	519	123,000	63,848,182	
3	2021	80	514	123,000	63,209,700	2,087
4	2021	81	509	123,000	62,571,218	
1	2022	82	504	123,000	61,932,736	
2	2022	83	498	123,000	61,294,255	
3	2022	84	493	123,000	60,655,773	2,004
4	2022	85	488	123,000	60,017,291	
1	2023	86	483	123,000	59,378,809	
2	2023	87	478	123,000	58,740,327	
3	2023	88	472	123,000	58,101,845	1,921
4	2023	89	467	123,000	57,463,364	
1	2024	90	462	123,000	56,824,882	
2	2024	91	457	123,000	56,186,400	
3	2024	92	452	123,000	55,547,918	1,838
4	2024	93	446	123,000	54,909,436	
1	2025	94	441	123,000	54,270,955	
2	2025	95	436	123,000	53,632,473	
3	2025	96	431	123,000	52,993,991	1,755
4	2025	97	426	123,000	52,355,509	
1	2026	98	420	123,000	51,717,027	
2	2026	99	415	123,000	51,078,545	
3	2026	100	410	123,000	50,440,064	1,671
4	2026	101	405	123,000	49,801,582	
1	2027	102	400	123,000	49,163,100	
2	2027	103	395	123,000	48,524,618	
3	2027	104	389	123,000	47,886,136	1,588
4	2027	105	384	123,000	47,247,655	
1	2028	106	379	123,000	46,609,173	
2	2028	107	374	123,000	45,970,691	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR PART E CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2028	108	369	123,000	45,332,209	1,505
4	2028	109	363	123,000	44,693,727	
1	2029	110	358	123,000	44,055,245	
2	2029	111	353	123,000	43,416,764	
3	2029	112	348	123,000	42,778,282	1,422
4	2029	113	343	123,000	42,139,800	
1	2030	114	337	123,000	41,501,318	
2	2030	115	332	123,000	40,862,836	
3	2030	116	327	123,000	40,224,355	1,339
4	2030	117	322	123,000	39,585,873	
1	2031	118	317	123,000	38,947,391	
2	2031	119	311	123,000	38,308,909	
3	2031	120	306	123,000	37,670,427	1,256
4	2031	121	301	123,000	37,031,945	
1	2032	122	296	123,000	36,393,464	
2	2032	123	291	123,000	35,754,982	
3	2032	124	286	123,000	35,116,500	1,173
4	2032	125	280	123,000	34,478,018	
1	2033	126	275	123,000	33,839,536	
2	2033	127	270	123,000	33,201,055	
3	2033	128	265	123,000	32,562,573	1,090
4	2033	129	260	123,000	31,924,091	
1	2034	130	254	123,000	31,285,609	
2	2034	131	249	123,000	30,647,127	
3	2034	132	244	123,000	30,008,645	1,007
4	2034	133	239	123,000	29,370,164	
1	2035	134	234	123,000	28,731,682	
2	2035	135	228	123,000	28,093,200	
3	2035	136	223	123,000	27,454,718	924
4	2035	137	218	123,000	26,816,236	
1	2036	138	213	123,000	26,177,755	
2	2036	139	208	123,000	25,539,273	
3	2036	140	202	123,000	24,900,791	841
4	2036	141	197	123,000	24,262,309	
1	2037	142	192	123,000	23,623,827	
2	2037	143	187	123,000	22,985,345	

## ESTIMATED LIABILITY FOR EEOICPA AS OF SEPTEMBER 30, 2011

### PROJECTED APPROVED CASES BY QUARTER FILED FOR PART E CASES

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2037	144	182	123,000	22,346,864	758
4	2037	145	176	123,000	21,708,382	
1	2038	146	171	123,000	21,069,900	
2	2038	147	166	123,000	20,431,418	
3	2038	148	161	123,000	19,792,936	675
4	2038	149	156	123,000	19,154,455	
1	2039	150	151	123,000	18,515,973	
2	2039	151	145	123,000	17,877,491	
3	2039	152	140	123,000	17,239,009	592
4	2039	153	135	123,000	16,600,527	
1	2040	154	130	123,000	15,962,045	
2	2040	155	125	123,000	15,323,564	
3	2040	156	119	123,000	14,685,082	509
4	2040	157	114	123,000	14,046,600	
1	2041	158	109	123,000	13,408,118	
2	2041	159	104	123,000	12,769,636	
3	2041	160	99	123,000	12,131,155	426
4	2041	161	93	123,000	11,492,673	
1	2042	162	88	123,000	10,854,191	
2	2042	163	83	123,000	10,215,709	
3	2042	164	78	123,000	9,577,227	343
4	2042	165	73	123,000	8,938,745	
1	2043	166	67	123,000	8,300,264	
2	2043	167	62	123,000	7,661,782	
3	2043	168	57	123,000	7,023,300	260
4	2043	169	52	123,000	6,384,818	
1	2044	170	47	123,000	5,746,336	
2	2044	171	42	123,000	5,107,855	
3	2044	172	36	123,000	4,469,373	176
4	2044	173	31	123,000	3,830,891	
1	2045	174	26	123,000	3,192,409	
2	2045	175	21	123,000	2,553,927	
3	2045	176	16	123,000	1,915,445	93
4	2045	177	10	123,000	1,276,964	
1	2046	178	5	123,000	638,482	
2	2046	179	-	123,000	-	

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**PROJECTED APPROVED CASES BY QUARTER FILED  
FOR PART E CASES**

Quarter Filed	Year	t	Total Approved Cases (a)	Case Amount (e)	Estimated Ultimate Compensation (f)	Approved Cases By Filed Year (g)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
3	2046	180	-	123,000	-	16
					\$ 8,768,245,091	71,287

- Notes: (a) Actual cases from Exhibit 3, Table 5, Column (14). Projected cases based on judgment.  
 (b) [ (4) × (5) ]  
 (c) Based on actual benefits from EEOCIPA.  
 (d) Annual sum of Column (4).

**ESTIMATED LIABILITY FOR EEO/ICPA  
AS OF SEPTEMBER 30, 2011**

**ESTIMATED CASES BY FISCAL YEAR FILED THAT ARE ULTIMATELY APPROVED UNDER EEO/IC (a)**

Fiscal Year Filed (1)	RECA (2)	BD (3)	CS (4)	CN - SEC (5)	CN - NONSEC (6)	BS (7)	PART E (8)	TOTAL (9)
7/01 - 9/01	139	2	1	37	-	-	-	179
10/01 - 9/02	1,728	412	23	1,322	21	114	-	3,620
10/02 - 9/03	735	366	9	1,221	168	347	-	2,846
10/03 - 9/04	584	268	10	687	484	100	-	2,133
10/04 - 9/05	595	183	6	876	870	54	-	4,509
10/05 - 9/06	470	164	7	1,406	1,228	43	-	7,484
10/06 - 9/07	1,107	144	8	1,663	984	105	-	8,484
10/07 - 9/08	657	113	11	2,394	697	98	-	7,735
10/08 - 9/09	462	110	5	2,165	499	65	-	6,279
10/09 - 9/10	335	84	5	2,808	373	52	-	5,988
10/10 - 9/11	307	50	2	3,770	314	62	-	6,373
10/11 - 9/12	291	80	8	3,764	305	66	-	7,347
10/12 - 9/13	253	72	8	3,567	266	60	-	6,977
10/13 - 9/14	223	65	8	3,370	234	57	-	6,626
10/14 - 9/15	199	59	8	3,173	208	54	-	6,286
10/15 - 9/16	178	54	5	2,977	186	51	-	5,952
10/16 - 9/17	159	49	4	2,780	167	48	-	5,625
10/17 - 9/18	145	44	4	2,583	150	44	-	5,306
10/18 - 9/19	130	40	4	2,386	135	41	-	4,989
10/19 - 9/20	117	36	4	2,189	121	38	-	4,675
10/20 - 9/21	105	32	4	1,993	108	34	-	4,363
10/21 - 9/22	93	29	4	1,796	96	31	-	4,053
10/22 - 9/23	83	26	4	1,599	85	28	-	3,745
10/23 - 9/24	72	23	4	1,402	74	24	-	3,437
10/24 - 9/25	61	19	4	1,205	63	21	-	3,128
10/25 - 9/26	51	16	2	1,009	52	18	-	2,819
10/26 - 9/27	41	12	-	812	42	14	-	2,510
10/27 - 9/28	31	10	-	615	32	11	-	2,204
10/28 - 9/29	21	7	-	418	22	7	-	1,897
10/29 - 9/30	11	4	-	221	11	4	-	1,591
10/30 - 9/31	2	-	-	37	2	1	-	1,298
10/31 - 9/32								1,173
10/32 - 9/33								1,090
10/33 - 9/34								1,007
10/34 - 9/35								924
10/35 - 9/36								841
10/36 - 9/37								758
10/37 - 9/38								675
10/38 - 9/39								592
10/39 - 9/40								509
10/40 - 9/41								426
10/41 - 9/42								343
10/42 - 9/43								260
10/43 - 9/44								176
10/44 - 9/45								93
10/45 - 9/46								16
<b>Total</b>	<b>9,385</b>	<b>2,573</b>	<b>162</b>	<b>56,245</b>	<b>7,998</b>	<b>1,693</b>	<b>71,287</b>	<b>149,342</b>

Notes: (a) Columns (2) through (8) are from Exhibit 4, Column (9) for the respective disease.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**ESTIMATED NUMBER OF PAID CASES BY FISCAL YEAR (a)**

Fiscal Year Paid	RECA	BD & BS	CS	CN - SEC	CN - NONSEC	PARTE	TOTAL
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
7/01 - 9/01	56	1	-	35	-	-	92
1001 - 9/02	1,795	388	17	1,331	4	-	3,535
1002 - 9/03	829	351	14	1,329	134	-	2,657
1003 - 9/04	595	273	5	737	482	-	2,092
1004 - 9/05	598	190	9	898	920	1,559	4,174
1005 - 9/06	499	166	5	1,496	1,267	2,217	5,650
1006 - 9/07	1,046	126	9	1,658	1,072	3,312	7,223
1007 - 9/08	747	104	8	2,371	701	4,714	8,645
1008 - 9/09	465	93	9	2,353	485	4,901	8,306
1009 - 9/10	340	67	5	2,584	341	4,461	7,798
1010 - 9/11	309	43	4	3,635	276	4,245	8,512
1011 - 9/12	291	80	8	3,764	305	2,834	7,282
1012 - 9/13	253	72	8	3,567	266	2,751	6,917
1013 - 9/14	223	65	8	3,370	234	2,668	6,569
1014 - 9/15	199	59	8	3,173	208	2,585	6,233
1015 - 9/16	178	54	5	2,977	186	2,502	5,901
1016 - 9/17	159	49	4	2,780	167	2,419	5,578
1017 - 9/18	145	44	4	2,583	150	2,336	5,262
1018 - 9/19	130	40	4	2,386	135	2,253	4,948
1019 - 9/20	117	36	4	2,189	121	2,170	4,637
1020 - 9/21	105	32	4	1,993	108	2,087	4,329
1021 - 9/22	93	29	4	1,796	96	2,004	4,022
1022 - 9/23	83	26	4	1,599	85	1,921	3,718
1023 - 9/24	72	23	4	1,402	74	1,838	3,413
1024 - 9/25	61	19	4	1,205	63	1,755	3,107
1025 - 9/26	51	16	2	1,009	52	1,671	2,802
1026 - 9/27	41	12	-	812	42	1,588	2,495
1027 - 9/28	31	10	-	615	32	1,505	2,193
1028 - 9/29	21	7	-	418	22	1,422	1,890
1029 - 9/30	11	4	-	221	11	1,339	1,587
1030 - 9/31	2	-	-	37	2	1,256	1,297
1031 - 9/32	-	-	-	-	-	1,173	1,173
1032 - 9/33	-	-	-	-	-	1,090	1,090
1033 - 9/34	-	-	-	-	-	1,007	1,007
1034 - 9/35	-	-	-	-	-	924	924
1035 - 9/36	-	-	-	-	-	841	841
1036 - 9/37	-	-	-	-	-	758	758
1037 - 9/38	-	-	-	-	-	675	675
1038 - 9/39	-	-	-	-	-	592	592
1039 - 9/40	-	-	-	-	-	509	509
1040 - 9/41	-	-	-	-	-	426	426
1041 - 9/42	-	-	-	-	-	343	343
1042 - 9/43	-	-	-	-	-	260	260
1043 - 9/44	-	-	-	-	-	176	176
1044 - 9/45	-	-	-	-	-	93	93
1045 - 9/46	-	-	-	-	-	16	16
Total	9,545	2,479	160	56,323	8,041	75,195	151,744

Notes: (a) Actual cases from Exhibit 3, Table 7. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected cases from Exhibit 5, Sheet 1 assuming no lag between the time a case is approved and the time it case is paid.

**ESTIMATED LIABILITY FOR EEOICPA  
AS OF SEPTEMBER 30, 2011**

**ESTIMATED CASES ELIGIBLE FOR MEDICAL EXPENSES**

Fiscal Year Paid	RECA (a)	BP (b)	CS (b)	CN - SEC (a)	CN - NONSEC (a)	BS (c)	PART B NEW MEDICAL (b)	PART E NEW MEDICAL (d)	PART B ONGOING MEDICAL (e)	PART E ONGOING MEDICAL (e)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
701-9/01	37				14			51		51
1001-9/02	606	310	12	554	407		1,482		1,530	
1002-9/03	280	209	11	280	407	19	926		2,369	
1003-9/04	314	122	8	239	132		811		3,041	
1004-9/05	384	84	4	283	294		1,053		3,911	2
1005-9/06	52	45	3	48	179		1,486		5,436	14
1006-9/07	731	54	3	424	424		1,486	1,368	4,700	1,501
1007-9/08	431	59	4	449	676		1,489	2,602	7,509	4,107
1008-9/09	273	63	5	651			1,218	3,088	8,240	6,957
1009-9/10	195	52	3	917			1,349	2,990	9,641	9,536
1010-9/11	179	34	3	1,057			1,427	2,753	9,852	11,714
1011-9/12	160	46	6	1,882			2,330	1,701	11,497	12,690
1012-9/13	139	42	6	1,784			2,179	1,651	12,871	13,529
1013-9/14	109	34	6	1,587			1,906	1,446	14,900	15,488
1014-9/15	109	34	6	1,587			1,906	1,551	14,900	14,818
1015-9/16	98	31	4	1,488			1,776	1,501	15,585	15,278
1016-9/17	87	28	3	1,390			1,649	1,451	16,070	15,624
1017-9/18	80	26	3	1,292			1,528	1,402	16,373	15,862
1018-9/19	72	23	3	1,193			1,407	1,352	16,505	15,998
1019-9/20	64	21	3	1,095			1,288	1,302	16,478	16,040
1020-9/21	58	19	3	1,000			1,176	1,252	16,406	16,000
1021-9/22	51	17	3	898			1,054	1,202	16,000	15,875
1022-9/23	46	15	3	809			938	1,152	15,572	15,682
1023-9/24	40	13	3	701			822	1,103	15,023	15,428
1024-9/25	34	11	3	603			706	1,053	14,391	15,118
1025-9/26	28	9	3	504			590	1,003	13,657	14,762
1026-9/27	23	7	3	406			473	953	12,839	14,364
1027-9/28	17	6	3	308			357	903	12,165	13,846
1028-9/29	12	4	3	209			244	853	10,896	13,473
1029-9/30	6	2	3	111			129	804	9,988	12,989
1030-9/31	1	1	3	18			21	754	8,939	12,485
1031-9/32								704	7,942	11,962
1032-9/33								654	7,020	11,424
1033-9/34								604	6,172	10,875
1034-9/35								554	5,316	10,337
1035-9/36								505	4,460	9,758
1036-9/37								455	4,051	9,196
1037-9/38								405	3,477	8,634
1038-9/39								355	2,963	8,074
1039-9/40								305	2,508	7,514
1040-9/41								255	2,108	6,957
1041-9/42								205	1,708	6,401
1042-9/43								156	1,308	5,846
1043-9/44								106	1,193	5,293
1044-9/45								56	971	4,740
1045-9/46								9	783	4,192
1046-9/47									625	3,684
1047-9/48									493	3,223
1048-9/49									355	2,808
1049-9/50									209	2,453
1050-9/51									226	2,099
1051-9/52									170	1,801
1052-9/53									126	1,537
1053-9/54									91	1,304
1054-9/55									65	1,099
1055-9/56									35	920
1056-9/57									21	783
1057-9/58									9	625
1058-9/59									6	518
1059-9/60									4	421
1060-9/61									2	339
1061-9/62									1	270
1062-9/63									1	214
1063-9/64									1	167
1064-9/65									1	129
1065-9/66									1	98
Total	5,028	1,468	112	24,715	3,524	647	35,494	42,904	392,168	473,785

Notes: (a) For Columns (2) through (7) and Column (9), actual cases are from Exhibit 3, Table 8 by disease. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected cases are from Exhibit 3, Sheet 1 times the selected percentage of cases filed by employee from Exhibit 3, Table 2 by disease.  
 (b)  $(C) + (E) + (F) + (G)$   
 (c) Ongoing medical new cases filed in Column (8) (Part B) or Column (9) (Part E) adjusted for mortality.



**ESTIMATED LIABILITY FOR EEO/CPA  
AS OF SEPTEMBER 30, 2011**  
**ESTIMATED DOLLARS PAID BY FISCAL YEAR**

Fiscal Year Paid	RECA (1)	RECA Paid on Behalf of DOJ (a) (2)	BD (a) (3)	CS (a) (4)	CS-SEC (a) (5)	CS-NONSEC (a) (6)	BS (a) (7)	BS-MEDICAL (a) (8)	PART B MEDICAL (b) (9)	PART B TOTAL (c) (10)	PART E COMP (d) (11)	PART E MEDICAL (e) (12)	PART E TOTAL (d) (13)	COMBINED PARTS B AND E TOTAL (d) (14)
1001-9001	2,400,000	-	150,000	2,550,000	5,175,000	-	-	-	3,822,401	351,549,880	-	-	-	8,125,000
1001-9002	891,488,888	-	57,243,554	2,550,000	198,384,926	400,000	-	-	14,726,405	321,353,136	-	-	11,903	351,549,880
1002-9003	29,355,987	-	3,943,112	2,100,000	193,674,632	170,000,000	-	-	22,984,045	270,612,119	-	-	18,502	270,630,621
1003-9004	29,609,545	-	5,482,664	1,200,000	186,830,357	71,005,000	-	-	108,509,144	270,612,119	-	-	18,502	270,630,621
1004-9005	25,885,413	57,601,644	2,172,900	1,200,000	181,506,540	184,506,540	-	-	370,015,177	572,738,317	-	-	278,256	573,016,573
1005-9006	55,858,420	81,541,664	24,171,500	1,200,000	217,063,167	184,506,540	-	-	390,705,177	572,738,317	-	-	278,256	573,016,573
1006-9007	51,918,750	77,820,238	18,297,663	1,005,000	233,564,118	154,173,537	-	-	55,884,272	567,994,317	-	-	4,609,807	568,604,124
1007-9008	37,632,083	45,375,397	14,947,500	1,025,000	316,516,281	100,926,429	-	-	69,271,657	665,694,347	-	-	477,337,651	1,063,031,998
1008-9009	23,818,869	36,347,424	13,725,000	1,350,000	323,208,779	68,637,500	-	-	100,767,588	467,851,160	-	-	19,785,702	487,636,862
1009-9010	12,500,000	20,668,719	9,900,000	650,000	330,673,610	48,321,145	150,000	-	647,679,325	864,032,999	-	-	462,172,591	1,070,602,590
1010-9011	15,350,137	30,699,680	6,940,071	30,250	312,582,468	48,321,145	-	-	259,740,216	860,338,930	338,211,651	-	462,172,591	1,268,986,225
1011-9012	14,550,000	29,100,000	12,000,000	1,200,000	564,570,000	45,712,886	-	-	183,944,314	831,075,600	348,611,073	-	812,133,554	1,280,900,027
1012-9013	12,650,000	25,300,000	10,800,000	1,200,000	535,050,000	39,859,239	-	-	209,032,603	833,925,842	338,395,364	-	873,883,570	1,260,204,275
1013-9014	11,100,000	22,600,000	9,600,000	1,200,000	510,000,000	33,248,886	-	-	147,264,045	796,392,524	378,648,816	-	873,883,570	1,260,204,275
1014-9015	9,800,000	19,800,000	8,500,000	1,200,000	476,000,000	31,248,886	-	-	249,382,282	768,398,230	378,648,816	-	873,883,570	1,260,204,275
1015-9016	8,900,000	17,800,000	7,800,000	750,000	446,900,000	27,878,836	-	-	264,654,862	774,572,698	307,748,236	-	812,133,554	1,260,204,275
1016-9017	7,950,000	15,900,000	7,300,000	600,000	416,970,000	25,012,235	-	-	276,998,991	750,727,226	297,532,527	-	1,078,260,518	1,560,036,270
1017-9018	7,250,000	14,500,000	6,600,000	600,000	387,450,000	22,485,183	-	-	286,449,385	725,344,569	287,316,818	-	1,078,260,518	1,560,036,270
1018-9019	6,600,000	13,200,000	6,000,000	600,000	362,000,000	20,127,584	-	-	277,003,944	697,141,324	276,689,409	-	1,078,260,518	1,560,036,270
1019-9020	5,800,000	11,600,000	5,200,000	600,000	334,400,000	18,272,886	-	-	270,083,944	667,141,324	266,689,409	-	1,078,260,518	1,560,036,270
1020-9021	5,250,000	10,500,000	4,800,000	600,000	298,800,000	16,249,988	-	-	298,307,180	634,610,168	256,669,691	-	1,078,260,518	1,560,036,270
1021-9022	4,650,000	9,300,000	4,350,000	600,000	269,370,000	14,474,285	-	-	297,096,437	599,824,390	246,453,982	-	1,078,260,518	1,560,036,270
1022-9023	4,150,000	8,300,000	3,900,000	600,000	239,850,000	12,742,285	-	-	293,489,304	560,023,589	236,238,273	-	1,078,260,518	1,560,036,270
1023-9024	3,650,000	7,200,000	3,500,000	600,000	210,300,000	11,101,286	-	-	292,459,304	521,489,304	219,181,285	-	1,078,260,518	1,560,036,270
1024-9025	3,150,000	6,200,000	3,000,000	600,000	181,800,000	9,462,279	-	-	279,429,375	482,272,192	215,581,485	-	1,078,260,518	1,560,036,270
1025-9026	2,650,000	5,100,000	2,400,000	600,000	151,290,000	7,866,279	-	-	269,146,473	438,627,752	205,591,145	-	1,078,260,518	1,560,036,270
1026-9027	2,150,000	4,100,000	1,800,000	600,000	121,770,000	6,304,365	-	-	256,821,490	392,846,855	195,375,436	-	1,078,260,518	1,560,036,270
1027-9028	1,650,000	3,100,000	1,500,000	600,000	92,250,000	4,739,948	-	-	242,615,667	348,776,615	185,159,277	-	1,078,260,518	1,560,036,270
1028-9029	1,150,000	2,100,000	1,000,000	600,000	63,700,000	3,127,948	-	-	228,472,624	300,449,304	164,944,108	-	1,078,260,518	1,560,036,270
1029-9030	600,000	1,100,000	500,000	600,000	33,210,000	1,565,530	-	-	208,027,624	246,090,538	154,241,908	-	1,078,260,518	1,560,036,270
1030-9031	100,000	200,000	100,000	600,000	5,535,000	283,871	-	-	189,781,134	195,900,005	154,512,600	-	1,078,260,518	1,560,036,270
1031-9032	-	-	-	-	-	-	-	-	171,146,107	171,146,107	144,296,891	-	1,078,260,518	1,560,036,270
1032-9033	-	-	-	-	-	-	-	-	153,547,688	153,547,688	134,081,182	-	1,078,260,518	1,560,036,270
1033-9034	-	-	-	-	-	-	-	-	133,869,328	133,869,328	113,577,645	-	1,078,260,518	1,560,036,270
1034-9035	-	-	-	-	-	-	-	-	121,599,324	121,599,324	101,669,764	-	1,078,260,518	1,560,036,270
1035-9036	-	-	-	-	-	-	-	-	107,272,251	107,272,251	93,238,445	-	1,078,260,518	1,560,036,270
1036-9037	-	-	-	-	-	-	-	-	94,047,565	94,047,565	81,398,629	-	1,078,260,518	1,560,036,270
1037-9038	-	-	-	-	-	-	-	-	81,919,940	81,919,940	70,440,408	-	1,078,260,518	1,560,036,270
1038-9039	-	-	-	-	-	-	-	-	69,800,835	69,800,835	59,844,408	-	1,078,260,518	1,560,036,270
1039-9040	-	-	-	-	-	-	-	-	60,800,835	60,800,835	52,535,509	-	1,078,260,518	1,560,036,270
1040-9041	-	-	-	-	-	-	-	-	51,932,631	51,932,631	44,130,800	-	1,078,260,518	1,560,036,270
1041-9042	-	-	-	-	-	-	-	-	43,958,022	43,958,022	36,915,581	-	1,078,260,518	1,560,036,270
1042-9043	-	-	-	-	-	-	-	-	36,915,581	36,915,581	31,924,091	-	1,078,260,518	1,560,036,270
1043-9044	-	-	-	-	-	-	-	-	31,924,091	31,924,091	26,933,424	-	1,078,260,518	1,560,036,270
1044-9045	-	-	-	-	-	-	-	-	26,933,424	26,933,424	22,942,358	-	1,078,260,518	1,560,036,270
1045-9046	-	-	-	-	-	-	-	-	22,942,358	22,942,358	19,951,445	-	1,078,260,518	1,560,036,270
1046-9047	-	-	-	-	-	-	-	-	16,830,371	16,830,371	14,296,891	-	1,078,260,518	1,560,036,270
1047-9048	-	-	-	-	-	-	-	-	13,949,907	13,949,907	11,915,445	-	1,078,260,518	1,560,036,270
1048-9049	-	-	-	-	-	-	-	-	10,969,349	10,969,349	9,325,636	-	1,078,260,518	1,560,036,270
1049-9050	-	-	-	-	-	-	-	-	8,978,382	8,978,382	7,428,948	-	1,078,260,518	1,560,036,270
1050-9051	-	-	-	-	-	-	-	-	6,975,759	6,975,759	5,843,588	-	1,078,260,518	1,560,036,270
1051-9052	-	-	-	-	-	-	-	-	4,932,640	4,932,640	4,091,176	-	1,078,260,518	1,560,036,270
1052-9053	-	-	-	-	-	-	-	-	3,699,146	3,699,146	3,051,189	-	1,078,260,518	1,560,036,270
1053-9054	-	-	-	-	-	-	-	-	2,992,640	2,992,640	2,466,342	-	1,078,260,518	1,560,036,270
1054-9055	-	-	-	-	-	-	-	-	2,086,084	2,086,084	1,689,424	-	1,078,260,518	1,560,036,270
1055-9056	-	-	-	-	-	-	-	-	1,412,193	1,412,193	1,139,922	-	1,078,260,518	1,560,036,270
1056-9057	-	-	-	-	-	-	-	-	988,877	988,877	802,289	-	1,078,260,518	1,560,036,270
1057-9058	-	-	-	-	-	-	-	-	681,891	681,891	559,137	-	1,078,260,518	1,560,036,270
1058-9059	-	-	-	-	-	-	-	-	496,408	496,408	402,727	-	1,078,260,518	1,560,036,270
1059-9060	-	-	-	-	-	-	-	-	307,258	307,258	250,157	-	1,078,260,518	1,560,036,270
1060-9061	-	-	-	-	-	-	-	-	201,157	201,157	165,129	-	1,078,260,518	1,560,036,270
1061-9062	-	-	-	-	-	-	-	-	129,615	129,615	106,165	-	1,078,260,518	1,560,036,270
1062-9063	-	-	-	-	-	-	-	-	82,295	82,295	67,594	-	1,078,260,518	1,560,036,270
1063-9064	-	-	-	-	-	-	-	-	51,608	51,608	42,168	-	1,078,260,518	1,560,036,270
1064-9065	-	-	-	-	-	-	-	-	31,958	31,958	26,165	-	1,078,260,518	1,560,036,270
1065-9066	-	-	-	-	-	-	-	-	19,637	19,637	16,038	-	1,078,260,518	1,560,036,270
Total	476,843,251	584,766,631	366,204,588	2,293,250	8,310,966,453	1,177,174,986	150,000	-	7,193,557,758	181,324,984,887	8,578,931,298	3,740,300,392	12,319,231,990	30,451,826,877

Notes: (a) Actual compensation dollars paid (b) CS column (c) through (f) from Exhibit 3, Table 6(b) - EEO/CPA. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected cases are based on the number of paid cases from Exhibit 5, Sheet 2 (b) Actual Part B medical dollars are from Exhibit 3, Table 6(b) - EEO/CPA. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected cases are based on the number of paid cases from Exhibit 5, Sheet 2 (c)  $(2) + (3) + (4) + (5) + (6) + (7) + (8) + (9)$  (d) Actual compensation dollars paid for Column (9) are from Exhibit 3, Table 6(b) - EEO/CPA. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected dollars are the number of approved cases from Exhibit 5, Sheet 1 times the selected Part E benefit of \$122,000 from Exhibit 4, Sheet 1 (b) (e) Actual Part E medical dollar are from Exhibit 3, Table 6(b) - EEO/CPA. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected dollars are the number of approved cases from Exhibit 5, Sheet 1 (f) Actual Part E medical dollar are from Exhibit 3, Table 6(b) - EEO/CPA. The last quarter in fiscal year 1011 is assumed to be the same as the prior quarter. Projected dollars are the number of approved cases from Exhibit 5, Sheet 1